Pain. Fatigue. Brain fog. A racing heart.

But blood pressure?
It’s silent - while exerting a constant mechanical force on one of the most delicate systems in the body: our brain.

From My Own Experience

I’ve seen this play out personally.

There was a time when I was taking T4-only thyroid medication, and my thyroid labs looked acceptable.

But my blood pressure told a different story - it was consistently registering a bit elevated and gradually increasing, without any obvious reason.

Diet hadn’t changed. Lifestyle hadn’t changed. It wasn’t until I threw out the T4 meds in 1999/2000 - and addressed my continuing sub-clinical hypothyroid state - that my blood pressure gradually returned to a solid baseline under 120/80.

That connection stayed with me.

Why Blood Pressure Matters

Our brain is not just an organ - it’s a dense network of microscopic vessels delivering oxygen, glucose, and nutrients with extraordinary precision.

Now imagine those vessels under constant pressure.

Not enough to trigger symptoms.
Not enough to send us to the doctor.
But just enough - over years - to cause subtle damage.

The resulting damage is:

• Micro-tears in vessel walls

• Reduced elasticity

• Impaired blood flow

• Breakdown of the blood-brain barrier

Over time, this can translate into:

• Reduced cognitive resilience

• Increased risk of vascular dementia

• Greater vulnerability to Alzheimer’s pathology

“I feel fine” doesn’t mean much here

One of the most misleading assumptions is that if blood pressure were a problem… you’d know it.

You wouldn’t.

Elevated blood pressure is often completely asymptomatic - even when it’s doing real damage.

And there is nuance:

• A “normal” reading at the doctor’s office doesn’t tell the full story

• Spikes during stress, poor sleep, or exertion often go unnoticed

• Nighttime blood pressure (when our brain is repairing itself) may be the most important - and the least measured

We can feel great… and still be quietly accumulating risk.

What This Means for APOE4 Carriers (and Anyone Who Cares About Their Brain)

To protect our cognitive future - blood pressure becomes important and a marker we want to understand clearly!

Why?

Because it amplifies everything else.

• Inflammation becomes more damaging

• Lipid transport issues become more consequential

• Microvascular dysfunction accelerates

It’s not just a number. It’s a damage multiplier.

Subtle Signs Something May Be Off

We may not “feel” high blood pressure - but our bodies sometimes give us subtle cues.

• Poor sleep quality or frequent nighttime waking

• Feeling wired but tired

• Head pressure (not pain - just pressure)

• Reduced exercise tolerance

• Increased heart rate variability instability

While these symptoms aren’t diagnostic - they’re clues worth paying attention to.

What to do (Without Overcomplicating It)

1. Measure - Don’t Assume

• Take your blood pressure at home

• Measure at different times (morning, evening, post-exercise)

• Pay attention to patterns - not just isolated readings

2. Hydration Matters

Even mild dehydration can elevate blood pressure.

• Start your day hydrated

• Maintain steady fluid intake - not just when thirsty

3. Vascular System Training

Our blood vessels respond to how we use them.

• Regular walking

• Resistance training

• Short bursts of higher intensity (as tolerated)

This is more than just fitness - it’s vascular conditioning.

4. Sleep Is a Blood Pressure Event

If your sleep is fragmented, your blood pressure likely is too.

• Prioritize consistent sleep timing

• Reduce late-night stimulation

• Pay attention to nighttime awakenings

5. Manage the “Invisible Load”

Stress doesn’t just affect your mind - it affects your pressure.

• Breathing practices

• Time outdoors

• Deliberate downshifting during the day

The Takeaway

Since we are building a plan for long-term brain health, we can’t overlook the quiet forces.

They’re often the ones that matter most. I used to assume my blood pressure was great. Now, I verify! Periodically I track pressure for several weeks at a time - several times a day - consistently at the same time.

That naturally raises the next question:

If this biology is real, how do we know whether it’s being pushed, or kept relatively quiet, in our own bodies?

We don’t yet have clinical tests that show lipid droplets in astrocytes or APOE lipidation in the brain. But we do have something useful: advanced lipoprotein panels that offer indirect signals about how hard the lipid system is being asked to work.

These markers are good context, and for APOE4 carriers, context matters.

A quick framing (important)

This post is not about chasing perfect numbers or defining universal targets.

What follows are the markers I personally watch, and the directional ranges that give me confidence that my APOE4 biology is operating in a relatively calm environment.

This is not a prescription.
It is how I translate mechanism into monitoring with available information I can get.

The markers I pay closest attention to

1. VLDL & VLDL-P

VLDL reflects triglyceride-rich particle flux and inflammatory lipid signaling, a burden APOE4 is less equipped to manage.

What I look for

• Low and stable VLDL

• No upward drift over time

• No post-meal or fasting spikes

For me, lower VLDL suggests a quieter peripheral lipid environment and less downstream stress on fragile lipid-handling pathways.

2. Remnant lipoproteins (one of the most important signals for me)

Remnant lipoproteins are highly inflammatory and APOE-dependent for clearance. When elevated, they are associated with endothelial dysfunction and increased inflammatory signaling.

What I aim for

• Remnant lipoproteins firmly in the low range

• Consistency over time, not one-off lows

Low remnants suggest that APOE4 is not being repeatedly activated to clear lipid debris in a hostile metabolic environment - a situation where it behaves worst.

3. Triglycerides

Why they matter

Triglycerides themselves are not inherently toxic. Chronically elevated levels, however, reflect impaired lipid utilization and increased remnant production - both of which amplify APOE4 stress.

What I look for

• Low fasting triglycerides

• Minimal variability

4. LDL-P and LDL-C (with perspective)

LDL often dominates lipid discussions, but I view it as context, not the primary signal.

• Particle number matters

• But metabolic environment matters more

• LDL is rarely the first system to fail in APOE4 biology

5. ApoB (with context)

ApoB reflects the total number of atherogenic particles circulating in the blood. Each LDL, VLDL remnant, and IDL particle carries one ApoB molecule.

For APOE4 carriers, ApoB provides a useful summary of particle burden, but it does not tell the whole story.

How I interpret it

• ApoB tells me how many particles are present

• It does not tell me how inflammatory, triglyceride-rich, or metabolically stressful those particles are

• It does not reflect lipid trafficking efficiency inside the brain
  
  When ApoB is low and remnants, VLDL, and triglycerides are low, that combination is reassuring.
  When ApoB is low but remnants are high, I care far more about the remnants.

6. ApoA1 (supporting capacity, not a shield)

ApoA1 is the main structural protein of HDL and reflects the body’s capacity for reverse cholesterol transport and lipid recycling.

• ApoA1 provides information about transport capacity

• Higher is not always better

• Function matters more than quantity

I monitor ApoA1 as a supporting signal, not as a guarantee of protection. Favorable ApoA1 does not override inflammatory lipid flux, poor metabolic control, or impaired lipid utilization.

7. Omega-3 Index (membrane resilience, not a nutrient checkbox)

The Omega-3 Index reflects the percentage of EPA and DHA incorporated into red blood cell membranes, serving as a proxy for long-term membrane composition and stability.

For APOE4 carriers, this marker is particularly relevant because APOE4 biology places chronic stress on lipid membranes, mitochondrial function, and glial support systems - all areas where DHA plays a foundational structural role.

Omega-3 Index is not simply a dietary or cardiovascular marker. It is a membrane quality signal.

It reflects how resilient cell membranes are in the face of oxidative stress, inflammatory signaling, and metabolic strain - conditions under which APOE4 tends to perform worst.

Low Omega-3 Index suggests membranes that are more rigid, more vulnerable to peroxidation, and less able to buffer lipid-related stress. For APOE4 carriers, that fragility matters.

What I look for

• Omega-3 Index in a robust, stable range (9%+)

• Consistency over time rather than episodic highs

• Alignment with low triglycerides, low remnant lipoproteins, and low inflammatory markers

A favorable Omega-3 Index does not override poor metabolic control or inflammatory lipid flux. But when it is adequate and stable - alongside quiet lipid signaling - it supports a more resilient, less reactive membrane environment.

8. HDL markers (with restraint)

HDL quantity does not equal HDL function.

Very low HDL-P can suggest reduced lipid recycling capacity, but HDL metrics are blunt tools. I view them as supporting indicators, not decision drivers.

9. Lp(a): context, not control

Lp(a) is genetically determined and largely non-modifiable. I track it for vascular awareness, but I don’t confuse it with lipid trafficking failure or neurodegenerative risk. I am one of the +/- 25% of the population who carries elevated lp(a). If you haven’t been tested for this highly atherogenic lipoprotein, don’t delay. It should be checked at least once. Levels usually remain fairly stable throughout life since elevated levels are genetic.

My personal “directional targets”

Again, these are not universal goals. They are the ranges that, I believe in my case, suggest a quieter lipid environment for APOE4 biology.

• Triglycerides: low and stable

• VLDL / VLDL-P: low

• Remnant lipoproteins: low

• LDL-P: interpreted in context, not isolation

• hs-CRP: low

• Fasting insulin: low

• Glycemic variability: minimal

• Sleep: deep, continuous, and protected

What these markers cannot tell me (and I’m clear about this)

Advanced lipid panels:

• Do not measure brain APOE directly

• Do not show glial lipid droplets

• Do not guarantee protection

  What they do tell me is whether the background metabolic environment is likely to amplify or dampen APOE4-related stress.

Quieting the system vs chasing numbers

My goal is:

• Reduced inflammatory lipid flux

• Less clearance burden

• Stable metabolic signaling

• Fewer repeated stress cycles

In other words: a quieter system that allows fragile lipid-handling pathways to keep up over time.

The bigger picture

Advanced lipoprotein panels don’t replace imaging or future molecular tools. But today, they are among the best accessible ways to infer whether APOE4 biology is being chronically challenged - or given room to function.

Combined with upstream strategies like membrane support, lipid replacement, metabolic stability, and sleep protection, these markers help me course-correct and give me a sense of control.

The takeaway

For me, learning how to read lipoprotein signals through an APOE4 lens has shifted prevention from fear-based interpretation to informed, systems-level monitoring.

Not certainty, but clarity.

And clarity is what facilitates calculated, common sense strategy that will hopefully retain my cognition and memory until that last breath.

For years, I did what many health-conscious people do.

Organic Flaxseed - and lots of it - was part of my regular diet.

Smoothies. Yogurt. Oatmeal. Sometimes 3–4 tablespoons a day - consistently, confidently - because I believed I was supporting my brain with omega-3s.

And for someone with APOE4/4, that felt like a smart move.

But it turns out, I was unknowingly working against myself.

The Unknown Factor: Sterol Hyperabsorption

What I didn’t know then - and what most people are never told - is that not everyone processes plant sterols the same way.

Some of us are sterol hyperabsorbers.

That means instead of efficiently eliminating plant sterols, we absorb them - and they accumulate in circulation - especially with APOE4s impaired cholesterol efflux.

The primary markers are:

• Beta-sitosterol

• Campesterol

At the extreme end of impaired sterol handling are rare genetic disorders like Niemann-Pick disease and sitosterolemia, where the body cannot process or eliminate certain lipids and sterols, leading to significant accumulation. So serious that - without treatment - premature death is the outcome.

That’s not what I’m suggesting here.

But it does illustrate an important point: sterol handling exists on a spectrum - and some of us sit further along that spectrum than we realize.

Most of us are never told this. We’re simply given generalized dietary advice and left to assume it applies equally.

Why This Matters (Especially for APOE4)

If you carry APOE4, lipid transport and metabolism are already different.

We are often told:

• Increase fiber

• Eat more plants

• Add seeds and nuts

• Focus on omega-3s

All good advice - in the right context.

But for a sterol hyperabsorber, loading up on foods like flaxseed, chia, nuts, and certain plant oils will increase sterol burden, not improve health.

So, you can be doing all the “right” things… and quietly moving in the wrong direction.

How I Found Out

I didn’t figure this out from a standard lipid panel. Everything looked… great!

It wasn’t until - in 2020 - I ran an advanced panel through Boston Heart Diagnostics that the picture became clear. My plant sterol markers were high.

As you can see above, not slightly - meaningfully. My cholesterol markers on this same test were Total Cholesterol 209, LDL-C 123, ApoB 103. Based on my goals today, everything was high - yet - for many folks not far off.

The Flaxseed Problem (for Some of Us)

Flax is often praised for:

• Fiber

• Lignans

• Omega-3 (ALA)

But it is also one of the highest dietary sources of plant sterols.

For a hyperabsorber, that matters.

In my case, what I thought was:
“I’m supporting my brain”

…was likely contributing to a risk exposure I was oblivious to.

Why You Should Know Your Pattern

This isn’t about demonizing healthy foods.

It’s about matching the input to your biology.

Two people can eat the same “clean” diet and have very different outcomes.

If you:

• Have persistently elevated LDL or ApoB despite a clean lifestyle

• Don’t respond well to statins alone

• See a strong response when adding ezetimibe

• Eat a diet high in nuts, seeds, and plant fibers

…it may be worth asking whether absorption - not production - is driving your numbers.

You Don’t Have to Guess

Ideally, this is tested.

The most direct way I’ve found is by measuring:

• Campesterol

• Beta-sitosterol

• Lathosterol

These markers help distinguish between cholesterol absorption and cholesterol production.

I used Boston Heart Diagnostics for this since most labs can’t test it. Even Emory University Hospital in Atlanta does not have a test to determine absorber status! But regardless of how you test, understanding your pattern can be a turning point.

The Takeaway

Health is not about doing more.

It’s about doing what matches you. For years, I was eating something, touted as a fantastic health food - and I was likely doing damage in the process.

Not everything that is “healthy” is healthy for everyone.

And sometimes, the most important step forward… is correcting what you’ve been doing all along.

If you carry APOE4 - or are working to optimize your cardiovascular and brain health - this is one area worth understanding.

Because the difference between absorption and production isn’t subtle.

It changes everything.

Two little-known compounds - palmitoylethanolamide (PEA) and luteolin - are attracting growing interest because they target a key driver of this process: the inflammatory feedback loop between mast cells and microglia.

Understanding this loop may open an entirely different way of thinking about brain protection.

The Brain’s Overlooked Immune Cells

When most people think about Alzheimer’s disease, they think about amyloid plaques and tau tangles.

But increasingly, researchers are focusing on the immune system of the brain.

Two types of cells appear particularly important:

Microglia
These are the brain’s resident immune cells. They patrol the nervous system, clear debris, and remove damaged synapses.

Mast cells
These cells sit near blood vessels and regulate inflammatory signaling.

Under normal circumstances, both of these cells are protective.

But when immune signaling becomes chronically activated, they can begin to amplify each other’s inflammatory responses.

This is where the mast cell - microglia loop comes into play.

The Mast Cell - Microglia Inflammatory Loop

Mast cells release powerful inflammatory molecules, including:

• histamine
• tryptase
• cytokines

These signals can activate nearby microglia.

Once activated, microglia release their own inflammatory mediators, including:

• IL-1β
• TNF-α
• reactive oxygen species

These molecules can further stimulate mast cells, creating a self-reinforcing inflammatory loop.

Over time, this process can create a chronic inflammatory environment that damages synapses and neurons.

For APOE4 carriers, whose immune signaling pathways appear to be more sensitive, this feedback loop may be particularly important.

Enter PEA

Palmitoylethanolamide (PEA) is a naturally occurring fatty-acid signaling molecule produced in the body.

It belongs to the same family as the endocannabinoids, although it does not bind directly to the classic cannabinoid receptors.

Instead, PEA activates a receptor called PPAR-alpha, which regulates inflammation and lipid metabolism.

When PEA levels rise, several important things happen:

• mast cells become more stable
• inflammatory cytokines decline
• microglial activation decreases
• oxidative stress is reduced

In other words, PEA helps restore immune balance rather than suppress immunity.

The goal is not to shut down the brain’s defenses, but to prevent them from becoming chronically overactive.

Luteolin: A Brain-Penetrating Flavonoid

Luteolin is a naturally occurring flavonoid found in foods such as:

• celery
• parsley
• artichokes
• chamomile

Unlike many plant compounds that struggle to reach the brain, luteolin crosses the blood–brain barrier.

Once in the brain, luteolin can:

• inhibit mast cell activation
• reduce histamine release
• suppress inflammatory cytokines
• calm microglial overactivation
• protect neurons from oxidative stress

These effects make luteolin a natural complement to PEA.

Why the Combination Matters

Individually, both compounds reduce inflammation.

Together, they appear to be synergistic.

PEA stabilizes mast cells and activates anti-inflammatory PPAR-alpha signaling.
Luteolin blocks inflammatory cascades such as NF-κB and cytokine release.

The result is a broader calming effect on the brain’s immune system.

Rather than suppressing immunity, the combination appears to shift immune cells back toward a more balanced, protective state.

A Surprising Link to Cholesterol Biology

One of the most intriguing aspects of PEA receives relatively little attention.

By activating PPAR-alpha, PEA may increase activity of cholesterol transport proteins such as:

• ABCA1
• ABCG1

These proteins move cholesterol out of immune cells and back into HDL particles - a process known as cholesterol efflux.

Why does this matter?

Because both atherosclerosis and Alzheimer’s disease involve immune cells overloaded with lipids.

In arteries, macrophages filled with cholesterol become foam cells, forming plaque.

In the brain, microglia can accumulate lipid droplets and become dysfunctional.

Supporting cholesterol efflux pathways may help restore healthier immune cell function in both systems.

For APOE4 carriers - who often have impaired lipid transport - this connection may be particularly important.

Clinical Use and Safety

In research and clinical settings, PEA is typically used in micronized or ultramicronized form, which improves absorption.

Typical dosing ranges:

PEA:
600–1200 mg per day

Luteolin:
50–100 mg per day

Some formulations combine both compounds in the same capsule.

Both compounds have an excellent safety profile, and side effects appear to be rare.

A Different Approach to Brain Protection

Most Alzheimer’s prevention strategies focus on metabolic health, lipid management, sleep, and exercise.

Those foundations remain essential.

But another layer is becoming increasingly clear: the regulation of brain immune signaling.

If microglia remain chronically activated for decades, they can gradually damage synapses and accelerate neurodegeneration.

Compounds such as PEA and luteolin offer a different approach - not by targeting amyloid directly, but by modulating the inflammatory environment in which neurodegeneration unfolds.

For APOE4 carriers, whose immune systems appear particularly sensitive, this strategy may prove especially relevant.

Alzheimer’s prevention may ultimately depend not only on clearing plaques, but on keeping the brain’s immune system balanced, calm, and capable of repair.

More on PEA:

https://pmc.ncbi.nlm.nih.gov/articles/PMC8157570/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9496237/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9405819/

You cannot manage what you don’t measure.

Most annual physicals include only a very limited set of lab tests. They are designed primarily to detect existing disease, not to help you understand how your biology is evolving over time.

If our goal is prevention - whether that’s cardiovascular disease, metabolic dysfunction, or Alzheimer’s disease - we need a much broader picture.

Why Standard Lab Panels Fall Short

A typical annual panel might include:

• total cholesterol

• fasting glucose

• a basic metabolic panel

That may be enough for basic screening, but it leaves out many of the markers that reveal early biological shifts years before disease appears.

For those of us trying to stay ahead of chronic disease, the real value lies in seeing what is changing before it becomes a diagnosis.

Accessing Comprehensive Testing

One service that makes broader testing accessible is Function Health. I was thrilled when that site was launched!

What makes their approach appealing is its simplicity:

• a large panel of biomarkers

• a single bundled price

• blood drawn locally at local labs

• results delivered through an online dashboard

For anyone interested in understanding their health more deeply, this kind of comprehensive panel can reveal a great deal more than a routine annual exam.

But obtaining the numbers is only the beginning.

The Problem With “Normal”

Most lab platforms (including Function Health) will simply tell you whether a value is within the reference range.

Those ranges are designed to detect disease.

They are not designed to identify emerging patterns.

And this is where many folks miss the real story.

Individual markers rarely provide the full picture. What matters far more is how markers relate to each other.

Pattern Recognition: Where the Insight Lives

Consider a common metabolic pattern.

Someone might have:

• fasting glucose in the normal range

• fasting insulin slightly elevated

• triglycerides gradually increasing

• HDL slowly drifting downward

None of these numbers may trigger a red flag on their own. But taken together, they form a recognizable pattern: early insulin resistance.

If this pattern is identified early, lifestyle changes can often reverse the trajectory long before diabetes ever develops.

or

Someone with:

• LDL cholesterol that appears acceptable

• triglycerides that are low

• HDL that looks healthy

At first glance, this panel appears reassuring.

But if ApoB is elevated, it tells a very different story. ApoB reflects the number of atherogenic particles circulating in the bloodstream, and that particle burden is one of the strongest drivers of plaque formation.

Without looking at ApoB - and without recognizing how it relates to the rest of the lipid panel - this risk can easily remain hidden.

Another pattern shows up often in people struggling with fatigue or cognitive fog.

You might see:

• a TSH that appears normal

• free T3 sitting at the lower end of the range

• reverse T3 somewhat elevated

• ferritin trending low

Each marker alone might be labeled “normal.” But together they can suggest reduced thyroid hormone utilization, something that can affect energy metabolism and brain function.

Again, the insight comes not from a single number but from the relationship between them.

Turning Data Into Understanding

With the vast amount of data obtained from my labs, I use LabClarity as my educational resource which provides context around biomarkers and helps highlight patterns that may otherwise be easy to miss. What I appreciate about it is that it brings this information into one place, providing context around biomarkers and helping highlight patterns that might otherwise be easy to miss.

It’s been an invaluable way for me to learn what my numbers may be telling me when viewed together.

The Real Value of Testing

For those of us focused on preventing cardiovascular disease, metabolic dysfunction, and neurodegenerative conditions, understanding the relationships between various markers can make all the difference.

And there’s another reality we live in: Physicians simply don’t have the time to sit down with patients and walk through dozens of biomarkers in detail. Which means that if we want to understand what’s happening in our own bodies, we have to take an active role. We have to become our own health advocates. And that starts with educating ourselves - learning what the markers mean, how they interact, and what signals they may be sending long before disease ever appears.

While none of my neighbors can see me, if they could they might reasonably conclude I’ve lost my mind. Each morning I turn on 1970s disco music, step onto a rebounder on my deck, and start bouncing.

It probably looks ridiculous.

But over time I’ve come to believe this simple habit may be one of the most underrated forms of movement for long-term health. Rebounding also lets me stack another habit at the same time. While I’m bouncing on the deck, I’m soaking up the morning and/or evening sunlight and getting a healthy dose of the sun’s red and near-infrared rays.

Here’s why I do it:

1. Rebounding stimulates the lymphatic system

Unlike the cardiovascular system, the lymphatic system has no pump.

Lymph fluid relies largely on muscle contraction and body movement to circulate. This fluid carries immune cells, metabolic waste products, and inflammatory debris away from tissues.

Gentle vertical acceleration - like the up-and-down motion of rebounding - appears particularly effective at stimulating lymph flow.

Early NASA work examining different exercise modalities noted that rhythmic bouncing movements produced strong lymphatic circulation with relatively low joint stress.

In practical terms, that means rebounding helps support:

• immune function
• detoxification pathways
• tissue fluid balance

While formal lymph-flow studies are limited, the biomechanics make intuitive sense. The shifting G-forces created by bouncing likely generate a gentle compression that helps move cellular waste out of tissues.

2. It is an unusually efficient cardiovascular exercise

Rebounding creates repeated cycles of acceleration and deceleration.

With each bounce, the body experiences small shifts in gravitational force. These shifts require constant engagement of stabilizing muscles and cardiovascular adjustments.

Studies comparing rebounding to treadmill running have found that rebounding can produce similar oxygen consumption with significantly lower impact forces.

That makes it appealing for:

• older adults
• people with joint issues
• those seeking low-impact aerobic exercise

In other words, you can achieve meaningful cardiovascular stimulation without pounding your joints.

3. It activates muscle and bone without high impact

Every bounce involves rapid cycles of:

• muscle contraction
• eccentric loading
• stabilization

These small forces repeatedly stimulate:

• postural muscles
• lower-body muscle fibers
• bone mechanoreceptors

Mechanical loading - even at modest levels - is one of the key signals that helps maintain bone density and muscle function with age.

Because rebounding distributes force across the trampoline surface, the impact is much lower than running or jumping on hard ground.

4. It may support metabolic health

Like other rhythmic aerobic activity, rebounding improves:

• circulation
• insulin sensitivity
• mitochondrial activity

But it also has an additional advantage: it is easy to do frequently.

Many people struggle to fit longer workouts into daily life. Rebounding allows you to accumulate meaningful metabolic movement in short bursts throughout the day.

Even five to ten minutes of rhythmic movement can improve glucose handling after meals.

5. It appears to improve balance and coordination

The unstable surface of a rebounder requires constant micro-adjustments of posture and balance.

These adjustments engage:

• core muscles
• stabilizing muscles of the hips and ankles
• proprioceptive feedback systems

Maintaining these systems becomes increasingly important as we age.

Balance training is strongly associated with fall prevention and long-term mobility.

6. Possible brain benefits

Direct research on rebounding and brain health is limited, but several mechanisms suggest potential benefits.

Rhythmic aerobic movement increases:

• cerebral blood flow
• neurotrophic signaling (such as BDNF)
• metabolic flexibility

Exercise also improves glymphatic clearance, the system the brain uses to remove metabolic waste during sleep - great for APOE4 carriers!

Rebounding may add an additional element: mild gravitational variation, which some researchers believe can influence fluid dynamics in the brain and spinal system.

This area remains largely speculative, but it is biologically plausible.

Why I do it

For me, rebounding checks several boxes at once.

It is:

• low-impact
• metabolically stimulating
• easy to do daily - and more than once
• surprisingly energizing

and FUN!

Ten minutes of bouncing is often enough to increase heart rate, improve circulation, and start the day with movement. I often add 3-5 lb weights.

Most importantly, it is something I can maintain consistently.

And consistency matters far more than perfection. In case you wonder, the rebounder I use is a 44” diameter Bellicon.

Addendum: The Astronaut / Neurology Insight

Researchers studying astronauts found that rhythmic vertical acceleration changes how cerebrospinal fluid moves through the brain and spinal canal.

In microgravity, CSF circulation becomes abnormal, which is one reason astronauts sometimes develop vision changes and intracranial pressure problems.

On Earth, rebounding produces repeated mild acceleration and deceleration forces that affect the same fluid dynamics.

The effect:

• alternating pressure gradients in the spine
• improved CSF pulsation
• improved venous drainage from the brain

These factors influence glymphatic flow.

Why This Matters for Brain Detox

The glymphatic system clears:

• beta-amyloid

• tau proteins

• metabolic waste

It works best when:

• CSF circulation is strong
• venous drainage is unobstructed
• lymphatic vessels in the neck are active.

Rhythmic body movement helps all three.

Why Rebounding Is Particularly Effective

Rebounding creates a unique combination:

Acceleration + decompression cycles

When you bounce:

1. Downward force
   → pushes lymph and venous blood upward

2. Upward release
   → reduces pressure and allows refill

This acts like a pump for lymph and venous return, which indirectly improves CSF exchange.

NASA researchers noted that rebounding can stimulate circulation more efficiently than running with lower oxygen demand.

A Simple “Brain Clearance Bounce”

You can add this small sequence after your rebound session.

2–3 minutes

1️⃣ Gentle bounce
2️⃣ Slow nasal breathing
3️⃣ Relax shoulders and neck

Then add:

30 seconds

Look slightly upward and gently extend the neck.

This position opens the jugular venous drainage pathways, which are critical for brain waste removal.

Why Neck Position Matters

The brain clears waste through:

• jugular veins
• meningeal lymphatic vessels

These run through the neck.

Poor posture or tight neck muscles can reduce drainage.

The gentle rebound + upright posture encourages venous outflow from the brain.

Before going further, it helps to clarify the terminology, because confusion around NAD is common.

NAD (nicotinamide adenine dinucleotide) is a molecule present in every cell. It exists in two forms: NAD (oxidized) and NADH (reduced). Together, they regulate redox balance, mitochondrial energy production, DNA repair, and cellular stress signaling.

NAD itself is not easily absorbed as an oral supplement in a way that meaningfully raises intracellular levels. Instead, most interventions aim to increase NAD through precursors:

• NMN (nicotinamide mononucleotide) – a direct precursor to NAD⁺

• NR (nicotinamide riboside) – another precursor that converts into NMN and then into NAD⁺

Both NMN and NR are used with the goal of raising intracellular NAD levels. They are not interchangeable with NAD itself, they are upstream building blocks.

When we discuss “boosting NAD,” we are generally referring to increasing cellular NAD availability via these precursor pathways.

NAD is not a “supplement topic.” It is a systems topic.

Nicotinamide adenine dinucleotide (NAD⁺/NADH) sits at the center of cellular energy metabolism. But the reason I’m writing about it in the context of APOE4 is more specific:

If APOE4 increasingly looks like a lipid trafficking vulnerability, then NAD is one of the most plausible upstream determinants of how well the system tolerates lipid load.

Lipid transport and recycling are not passive processes. They require energy, intact redox balance, functional mitochondria, and adequate cellular housekeeping. NAD touches all of those domains.

The core connection: lipid trafficking is energy-expensive

APOE4 vulnerability is often described as “lipid handling gone wrong.” But the practical question is: what makes lipid handling fail?

In the real world, lipid trafficking becomes pathological when cells cannot:

• oxidize and utilize lipids efficiently

• remodel and repair membranes

• clear damaged lipid and protein complexes

• maintain a stable inflammatory set point

All of those functions become strained when NAD availability falls.

What recent research is emphasizing

Across animal, mechanistic, and translational work, three themes are showing up repeatedly:

1) NAD depletion appears to be part of the Alzheimer’s biology, not just aging background noise

Multiple lines of research point to disturbed NAD metabolism in Alzheimer’s models and human AD biology, including increased NAD consumption in inflammatory glial environments (e.g., CD38 induction in astrocytes/microglia around pathology).

2) Boosting NAD can improve mitochondrial stress responses and cellular resilience in AD models

A 2024 paper reported that NMN (an NAD⁺ precursor) improved mitochondrial stress response pathways in an Alzheimer’s context via ATF4-dependent mitochondrial UPR signaling.

Other recent mechanistic work highlights new regulators of brain NAD levels (including astrocyte-linked pathways involving CD38), with tauopathy protection in mouse models when brain NAD is augmented.

3) Human data are emerging.

A randomized placebo-controlled trial of nicotinamide riboside (NR) in older adults with MCI showed that NR increased blood NAD levels and was well tolerated, but did not produce a clear cognitive improvement over the short study duration.

That pattern matters: NAD may be upstream and permissive. It may shift biology and resilience before it shifts test scores - especially over short windows.

Why NAD matters specifically for APOE4 lipid trafficking

Here is the simplest way to frame it:

APOE4 struggles most when lipid handling occurs in a hostile environment.
NAD is one of the strongest determinants of whether the environment is hostile or permissive.

1) NAD supports mitochondrial lipid utilization

When NAD is low, mitochondrial throughput declines. Fatty acid oxidation and energy production become constrained, and lipids are more likely to be diverted into storage (lipid droplets) rather than processed. In glial cells, this shift is tightly linked to inflammatory reprogramming.

2) NAD supports membrane maintenance and repair

Membranes are not static. They are constantly remodeled, repaired, and replaced. That’s the premise of Lipid Replacement Therapy. NAD-dependent enzymes and NAD-linked metabolic capacity influence whether membrane repair is robust or brittle, especially under oxidative stress.

3) NAD influences whether glia resolve lipid stress or amplify it

In the Alzheimer’s literature, NAD-consuming CD38 is repeatedly implicated in inflammatory glial environments. CD38 dysregulation in the brain is increasingly studied as an immunometabolic checkpoint, and recent work has explored CD38-targeted strategies that restore metabolic fitness and reduce neuroinflammation in AD models.

For APOE4, this matters because microglia and astrocytes are the front line of lipid recycling. If they become energetically compromised, lipid trafficking becomes inflammatory trafficking.

“Very recent” developments worth watching

A cluster of 2025 publications has accelerated interest in NAD as a disease-modifying axis, including mechanistic work describing NAD regulation through astrocyte pathways and tauopathy protection.

There is also emerging preclinical work exploring pharmacologic preservation of NAD balance with striking claims in animal models (including the suggestion that delayed intervention can still shift pathology). These are early-stage results and should be interpreted as hypothesis-strengthening rather than practice-changing.

At the review level, the broader scientific consensus trend is also visible: NAD augmentation is increasingly framed as a multi-target strategy relevant to neurodegeneration through energy metabolism, proteostasis, and neuroinflammation.

How I integrate NAD into the lipid trafficking framework.

I view NAD as the energetic layer that helps determine whether:

• lipid trafficking remains efficient or congested

• membranes remain resilient or oxidizable

• glia remain homeostatic or reactive

• autophagy keeps pace with damage or falls behind

In other words, NAD doesn’t replace the lipid story. It supports the conditions under which the lipid story stays quiet.

Where this leaves us.

The NAD story is compelling because it is coherent across multiple levels of biology. But it is also important to be intellectually honest:

• Human RCTs to date are small and short

• Cognitive endpoints may lag behind mechanistic changes

• Optimal dosing, duration, and target populations are not settled

Still, for APOE4 prevention-minded individuals, NAD is difficult to ignore precisely because it maps onto the vulnerabilities we are now zeroing in on: lipid trafficking stress, mitochondrial fragility, glial reactivity, and impaired repair capacity.

References:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11470026/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12866132/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/

Disclaimer: This post is for educational discussion only and does not constitute medical advice. NAD-related interventions (including precursors such as NMN/NR or NAD infusions/injections) can have risks and may not be appropriate for everyone. Decisions should be made with a qualified clinician, particularly for individuals with complex medical histories or those using off-label therapies

A recently published paper adds to that picture by examining how the gut microbiome differs between APOE4 carriers and non-carriers in cognitively healthy older adults. The differences are subtle, but they matter because they point to low-risk, high-upside ways APOE4 carriers can reduce inflammatory pressure and support the systems that APOE4 strains over decades.

What the study looked at

Researchers analyzed stool samples from 114 cognitively healthy adults (average age ~77) and compared APOE4 carriers with non-carriers. Importantly, these were not people with Alzheimer’s. These were older adults aging normally.

That matters, because it shifts the question from disease to risk biology.

The key finding

APOE4 carriers did not have worse overall microbiome “richness” (how many species live in the gut). But they did show differences in microbial composition compared to non-carriers.

In other words:

• It’s not about how many microbes you have

• It’s about which ones dominate and what they do

Notably, the study highlighted species differences tied to short-chain fatty acid (SCFA) pathways, including butyrate—a compound associated with:

• Gut barrier integrity

• Immune regulation

• Microglial balance

• Neuroinflammation control

This aligns with the broader pattern across APOE–microbiome research: the most consistent signal isn’t one “magic bacteria,” it’s function - inflammation tone, barrier integrity, and microbial metabolites like SCFAs.

Where lipid transport fits in

APOE4’s core problem in the brain isn’t “cholesterol is bad.” It’s that lipids and cholesterol aren’t moved around as efficiently, especially for repair and maintenance.

Think of ApoE as a delivery system: neurons and synapses rely on lipid transport for membrane repair, signaling, and resilience. APOE4 tends to be a less efficient delivery version, and it’s more vulnerable when inflammation is high.

This is where the gut matters.

The gut can worsen or ease APOE4’s lipid-transport burden in 3 practical ways:

1) Inflammation is a headwind for lipid handling
A disturbed microbiome can increase inflammatory signaling through the immune system. Chronic, low-grade inflammation makes the brain’s support cells (astrocytes and microglia) less “repair oriented,” which is the exact environment where APOE4 struggles most.

2) The gut helps regulate bile signaling and fat processing
Our gut microbes interact with bile acids (which start as cholesterol). Those bile-related signals influence metabolic tone and inflammatory set points. When that system is off, lipid handling tends to get messier, systemically and in the brain.

3) SCFAs help keep the barrier intact
Butyrate-supportive ecosystems are linked with healthier gut barrier function and calmer immune signaling. A better barrier typically means fewer inflammatory triggers leaking into circulation - again lowering the pressure on APOE4’s already-fragile risk biology.

Bottom line: Supporting gut function can lower the inflammatory “noise” that makes APOE4 lipid transport inefficiency more damaging over time.

What we can reasonably extrapolate (and what we can’t)

Taken in context with other studies in humans and APOE-targeted replacement mice, this paper supports a larger pattern:

• APOE4 is associated with a pro-inflammatory bias

• The gut microbiome appears to be one contributor to that bias

• SCFA-supportive ecosystems may be less supported in APOE4 carriers

• That may amplify vulnerability over decades

Crucially, the microbiome is modifiable - unlike our genes.

Where TUDCA fits into the APOE4 gut-lipid picture
An often-overlooked piece of gut health is bile flow and bile signaling, which sits at the intersection of cholesterol metabolism, microbial ecology, and inflammation. TUDCA (tauroursodeoxycholic acid) supports healthy bile composition and flow, helping the body properly emulsify fats and recycle cholesterol-derived bile acids. This matters for APOE4 because bile acids are not just digestive detergents - they are signaling molecules that influence metabolic tone, inflammatory pathways, and gut microbial balance. When bile flow is sluggish or bile signaling is disrupted, downstream effects can include dysbiosis, impaired lipid handling, and increased inflammatory burden - all areas where APOE4 carriers are more vulnerable. By supporting bile physiology, TUDCA may indirectly reduce stress on lipid transport systems and help create a gut environment that is more compatible with long-term metabolic and brain resilience.

An APOE4-focused action plan (low risk, high upside)

Rather than chasing individual bacteria, the goal is to shift gut function, not taxonomy.

Start with data

If you’ve never done a microbiome stool test, this is an excellent place to start. Many of us have taken antibiotics at some point, and those are well known to disrupt beneficial gut bacteria. A microbiome test removes the guesswork and allows you to build a targeted, informed action plan.

Looking back at my own results, I learned I was low in key strains such as Akkermansia and L. reuteri, which helped me adapt my strategy with precision. Tiny Health, a leader in microbiome testing, offers a simple at-home test with clear, actionable insights. Use code APOE44 to save $20 on your test.

1) Support short-chain fatty acid production

SCFAs, especially butyrate, are one of the most consistent protective signals in gut–brain research.

Practical ways to do this:

• Gradually increase fermentable fiber diversity, not just quantity

• Examples: overnight oats or barley (beta-glucans), legumes if tolerated, psyllium, PHGG, inulin, cooked-and-cooled starches

• Go slow—tolerance matters more than perfection

2) Use fermented foods strategically

Small, regular amounts can help reshape microbial signaling:

• Kefir, yogurt, sauerkraut, kimchi, fermented vegetables

• Start with tablespoons, not bowls

• Back off if histamine or GI symptoms flare

3) Think “polyphenols feed microbes”

Polyphenols can shift microbial function even when species changes are subtle:

• Berries, cocoa, green tea, herbs, spices, pomegranate

4) Protect the gut barrier

A stressed gut barrier can amplify systemic and neuroinflammation.

• Minimize ultra-processed foods (and pay attention to emulsifiers if sensitive)

• Be mindful with alcohol

• Prioritize sleep and circadian consistency

• Ensure adequate omega-3 intake

5) Be intentional after antibiotics or illness

Treat recovery periods as “rebuild windows”:

• Re-emphasize fibers, fermented foods, and polyphenols

• Don’t assume you “bounce back” automatically

What I personally do to support gut health

After years reading about the gut–brain connection (and taking a microbiome test), I’ve landed on an approach that’s simple, consistent, and physiologically sensible rather than extreme.

My non-negotiable foundation is real food - focused on supporting the gut lining and microbial diversity:

• Homemade kefir (which I tolerate well and make regularly)

• Non-pasteurized sauerkraut for natural lactobacilli and fermentation byproducts

• A diet that excludes ultra-processed foods, sugar, simple carbs, and seed oils

On top of that base, I use a few targeted supports:

• Butyrate (mornings, empty stomach) to support gut barrier integrity

• TUDCA (with breakfast) to support bile flow and fat digestion—an often-overlooked part of gut health

• Akkermansia (Pendulum) and L. reuteri as targeted supports rather than “dozens of strains” … both also taken on an empty stomach.

Where saffron fits in (and why I’ll continue using it)

One addition that’s been surprisingly impactful for me is saffron. (wrote about its potent effects in a previous post.)

From a metabolic perspective, saffron supports:

• insulin sensitivity

• reduced inflammatory signaling that interferes with glucose regulation

• healthier gut–liver–bile signaling (which affects metabolic control)

The bigger picture

For APOE4 carriers, gut health isn’t just digestive health. It’s brain health.

Genes load the gun, but environment pulls the trigger - and the microbiome is one of the most powerful, most modifiable environmental levers we have.

And unlike many interventions in Alzheimer’s prevention, improving gut ecology is:

• low risk

• multi-system beneficial

• compatible with almost every other strategy

This isn’t about doing everything.
It’s about doing enough of the right things, consistently - and paying attention to how our body responds.

References:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12737834/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6593891/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12081816/
https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.619051/
https://www.sciencedirect.com/science/article/pii/S2589004224015736

Triglycerides are often discussed as if they’re metabolic waste, something to suppress aggressively. But biologically, triglycerides are part of the system that keeps lipids contained, buffered, and well-behaved. Treating them as disposable misses what they actually do - both in circulation and inside cells, including in the brain.

If this sounds familiar, it should. I made a similar point in an earlier post on statins: lipid biology rarely rewards absolutism. “Lower” can be helpful - until it isn’t. Triglycerides may be the clearest example of where that line gets crossed.

And for anyone thinking about Alzheimer’s risk, APOE genotype, or aging physiology, this nuance matters.

Triglycerides aren’t just a blood number

Yes, fasting triglycerides largely reflect triglyceride-rich lipoproteins (mostly VLDL). And yes - chronically elevated triglycerides in midlife often signal insulin resistance, excess remnant particles, fatty liver, and higher cardiovascular risk.

That part of the story is real.

But triglycerides are also the backbone of lipid droplets - dynamic intracellular organelles found in liver, muscle, immune cells, and importantly, astrocytes in the brain. Lipid droplets are not passive fat storage. They are a containment system.

They exist to:

• safely sequester fatty acids

• prevent lipotoxicity

• buffer oxidative stress

• supply energy during demand

• protect mitochondria from overload

In other words, triglycerides are one of the ways biology keeps lipids from misbehaving.

Lipid droplets need triglycerides to stay functional

Here’s where things get interesting - and where the “lower is better” narrative starts to wobble.

Recent cellular work shows that the ratio of triglycerides to cholesteryl esters inside lipid droplets affects their physical state. When triglycerides are depleted—such as during sustained lipolysis or severe energy restriction - lipid droplets can undergo phase transitions, shifting toward more rigid, liquid-crystalline states.

Why does that matter?

Because fluid lipid droplets behave differently than rigid ones. Organization matters. Mobility matters. And rigidity tends to show up under metabolic stress.

Triglycerides, in sufficient proportion, help keep lipid droplets fluid and functional. This is not about excess. It’s about balance.

That idea aligns surprisingly well with broader work on phase separation and membrane dynamics, a conceptual framework explored by researchers like Doris Loh and discussed in a previous post. The takeaway isn’t that triglycerides are “protective” in isolation - but that biology cares about structure and organization, not just concentrations.

APOE, triglycerides, and why genotype matters

This is where the Alzheimer’s conversation becomes unavoidable.

Astrocytes - the brain’s lipid managers- use APOE to traffic lipids. Under lipogenic conditions, APOE itself associates with lipid droplets. When APOE is dysfunctional, lipid droplet handling changes.

Astrocytes expressing APOE4, in particular, form lipid droplets that are more vulnerable to oxidative damage and impaired turnover. That suggests lipid containment and buffering may already be compromised in APOE4 brains.

So what happens if we push triglycerides aggressively lower - without regard to cellular lipid handling?

We don’t fully know. But we should at least pause.

The APOE2 paradox (and why it should make us think)

Here’s a fact that surprises many people:

APOE2 is the most protective genotype for Alzheimer’s disease risk.

And yet - APOE2 homozygotes (2/2) are also the group most prone to elevated triglycerides and delayed remnant clearance.

I stumbled onto this while analyzing my APOE2/2 husband’s lipid profile. His triglycerides consistently run higher, increasing his cardiovascular risk, yet his genetics are strongly protective against Alzheimer’s disease.

That does not mean high triglycerides are beneficial. It means the relationship between triglycerides, lipid trafficking, and brain health is not linear.

If the genotype most protective against Alzheimer’s tends to tolerate - or even trend toward - higher triglycerides, then blanket claims that triglycerides should be driven as low as possible for everyone deserve closer scrutiny.

Context matters. Genetics matters. Mechanism matters.

And yes - as a 4/4 myself, I did manage one major strategic win: choosing a 2/2 husband to offset our children’s AD risk. A rare gem indeed - only about 0.5–1% of the population.
Genetics is humbling… but not entirely without humor and irony.

When low triglycerides may actually be a signal

Several large observational studies in older adults have shown something deeply unfashionable:

• Very low triglycerides are associated with higher dementia risk

• In the “oldest old,” higher triglycerides correlate with lower risk of cognitive decline, frailty, and mortality

• Low triglycerides have been associated with increased hemorrhagic stroke risk

This does not mean anyone should aim to raise triglycerides. It means that in late life - or in people who are under-fueling, over-restricting, or stacking triglyceride-lowering interventions - very low triglycerides may reflect loss of metabolic reserve, not metabolic excellence.

Medicine is good at lowering numbers. It’s less good at asking what those numbers represent in context.

APOE4, DHA delivery, and lipid transport

Work by researchers like Dr. Hussein Yassine has highlighted another important point: lipid delivery to the brain differs by APOE genotype.

In DHA supplementation studies, APOE4 carriers show reduced enrichment of CSF omega-3s compared with non-carriers - suggesting transport, not intake, may be the bottleneck.

This reinforces the broader theme:
In APOE4, lipid handling matters as much as lipid levels.

Driving triglycerides ever lower without considering how lipids are trafficked, stored, and delivered - especially in the brain - may solve one problem while quietly creating another.

So what’s the sane position?

Here’s my thought:

• In midlife, elevated triglycerides often reflect metabolic dysfunction and should be addressed - primarily by fixing insulin resistance, not just suppressing the number.

• In later life, very low triglycerides can be a warning sign of under-fueling, frailty, or diminished resilience.

• For APOE4, lipid organization and delivery may matter more than achieving textbook-perfect fasting values.

Biology rarely rewards extremes.

When might triglycerides be “too low”?

There is no universally agreed cutoff - but observational studies linking low TG to dementia, frailty, or hemorrhagic stroke often involve fasting triglycerides below ~60 mg/dL, and sometimes below 50 mg/dL, particularly in older adults.

Low triglycerides deserve a second look when they coexist with:

• unintentional weight loss or sarcopenia

• aggressive carbohydrate or fat restriction

• excessive fasting in older age

• fatigue, poor sleep, cold intolerance

• low insulin, low leptin, or other signs of under-fueling

This is not a call to raise triglycerides.
It is a call to stop celebrating low numbers without context.

Closing thought

Triglycerides are not merely a risk marker to be crushed into submission. They are part of the system that keeps lipids organized, contained, and less toxic - both in plasma and inside cells.

If APOE2 homozygotes can carry higher triglycerides yet enjoy the lowest Alzheimer’s risk, that alone should make us skeptical of one-size-fits-all lipid dogma.

What Did the Study Find?

Published in Nature after more than a decade of work, this study shows that:

• Lithium is naturally present in the brain. Until now, most research treated lithium mainly as a pharmaceutical used in psychiatric conditions like bipolar disorder. But this team demonstrated that lithium exists at biologically meaningful levels in healthy brains.

• Lithium levels drop early in Alzheimer’s. In both human brain tissue and animal models, lithium depletion was one of the first detectable changes associated with cognitive impairment.

• Plaques may sequester lithium. Amyloid-beta, the early hallmark protein aggregates in Alzheimer’s, binds lithium - reducing its availability in the brain.

• In mice, lithium deficiency accelerated pathology. Lower lithium levels triggered inflammation, synaptic loss, myelin degradation, and memory decline, all classic Alzheimer’s features.

• A lithium compound reversed disease markers in mice. Using a compound called lithium orotate that avoids being sequestered by amyloid, researchers were able to restore memory and reduce pathology in mice - at doses far lower than those used in bipolar treatment.

This last point is especially important because lithium in high doses (such as lithium carbonate used in psychiatric settings) can be toxic, especially in older adults. The notion here is micro- or physiological dosing of lithium, not high, mood-stabilizing levels.

Why Lithium Might Work: The GSK-3 Connection

One reason lithium keeps resurfacing in Alzheimer’s research - despite decades of neglect - is its relationship to a powerful regulatory enzyme called GSK-3 (glycogen synthase kinase-3).

What is GSK-3?

GSK-3 is a master regulatory kinase - an enzyme that controls the activity of many other proteins by phosphorylating them. In a healthy brain, GSK-3 activity is tightly restrained. In Alzheimer’s disease, it becomes chronically overactive.

That matters because GSK-3 sits at the crossroads of several core Alzheimer’s processes:

• Tau pathology:
  GSK-3 is one of the primary enzymes that hyperphosphorylates tau. Excessive GSK-3 activity destabilizes microtubules, promotes neurofibrillary tangles, and closely tracks cognitive decline.

• Amyloid biology:
  GSK-3 promotes amyloid-β production and is itself activated by amyloid, creating a self-reinforcing feedback loop that accelerates pathology once it begins.

• Neuroinflammation:
  Overactive GSK-3 drives pro-inflammatory signaling (via NF-κB and cytokines), keeping microglia in a chronically activated, neurotoxic state.

• Insulin resistance in the brain:
  Insulin signaling normally suppresses GSK-3. In Alzheimer’s - and particularly in APOE4 brains - impaired insulin signaling removes this brake, allowing GSK-3 to remain switched “on.”

• Mitochondrial dysfunction and synaptic loss:
  GSK-3 overactivity disrupts energy production, impairs synaptic plasticity, and promotes neuronal apoptosis.

In short, GSK-3 doesn’t cause one Alzheimer’s feature - it coordinates many of them.

Where lithium fits in

Lithium is one of the most potent known inhibitors of GSK-3.

At low, non-psychiatric doses, lithium:

• Directly inhibits GSK-3 activity

• Indirectly suppresses GSK-3 by improving insulin signaling

• Reduces tau hyperphosphorylation

• Dampens neuroinflammatory signaling

• Supports autophagy and mitochondrial function

This is a fundamentally different mechanism than targeting amyloid plaques or tau tangles after the fact. Lithium acts upstream, at a control node that influences both.

Importantly, this does not require the high serum lithium levels used in bipolar disorder, levels that carry real toxicity risks. The emerging Alzheimer’s literature increasingly points toward micro-dosing, where GSK-3 is gently down-regulated rather than shut down.

Why this connection is often missing from the literature

Most Alzheimer’s papers focus on isolated pathways such as tau, amyloid, inflammation, metabolism, rather than the enzymes that integrate them. GSK-3 often appears in the background of these studies, but rarely as the central unifying factor.

When viewed through a systems-biology lens, however, the logic becomes difficult to ignore:

If Alzheimer’s represents a state of chronic GSK-3 overactivation, then lithium’s long-observed neuroprotective effects suddenly make sense.

This doesn’t make lithium a cure, but it does make it a rational intervention worth serious attention.

Bottom line

Lithium’s relevance to Alzheimer’s is not mysterious or anecdotal. It stems from its ability to modulate GSK-3, a central enzyme linking tau pathology, amyloid biology, inflammation, insulin resistance, and neuronal survival. Seen this way, lithium is not an outlier, it is one of the few interventions that acts where many Alzheimer’s pathways converge.

Why Is This Important?

For decades, Alzheimer’s research has focused heavily on amyloid plaques and tau tangles, with limited success in changing clinical outcomes. This study proposes a fundamentally different angle:

Instead of focusing solely on downstream pathology, look upstream to an essential trace element whose deficiency may open the door to neurodegenerative cascades.

Some prior population studies had hinted that areas with higher natural lithium in drinking water had lower dementia rates, and long-term lithium therapy in psychiatric patients has been associated with lower Alzheimer’s incidence.

Mechanisms by Which Lithium Might Help

Lithium has been studied for its neuroprotective properties for years. Preclinical and clinical research has shown that it may:

• Inhibit GSK-3, an enzyme involved in both amyloid and tau pathology.

• Reduce neuroinflammation and oxidative stress.

• Improve cell survival, mitochondrial function, and autophagy - all processes implicated in Alzheimer’s.

• Correlate with slower cognitive decline in some human studies.

The new Harvard work extends these concepts by suggesting that the brain actually needs a baseline lithium level for normal function - much like essential vitamins or minerals - and that depletion is not just an association but a contributor to disease progression.

Important Caveats

This research is still in early stages:

• Most of the dramatic effects were observed in mouse models, which don’t always translate directly to humans.

• Clinical trials in humans for Alzheimer’s prevention or therapy using lithium have been limited and mixed, and no lithium compound is currently approved for Alzheimer’s treatment.

• The form of lithium used in the mice (e.g., lithium orotate or other amyloid-evading compounds) has not yet been tested in robust, controlled human trials.

Where this field might head next:

The implications of this research extend beyond a single study:

• Biomarker development: Measuring lithium levels in blood or cerebrospinal fluid might help identify individuals at risk for Alzheimer’s earlier.

• New therapeutic strategies: Designing lithium compounds that avoid sequestration and toxicity could lead to treatments that modify the disease process rather than just its symptoms.

• Nutritional neuroscience reconsidered: If lithium is truly acting like an essential nutrient for brain health, baseline requirements and dietary/lifestyle factors may gain newfound importance.

Bottom Line

Emerging research is reframing lithium from a psychiatric drug to a potential missing piece in our understanding of Alzheimer’s disease. While it’s too early to declare it a cure or a clinically validated therapy, the idea that lithium deficiency might help explain and potentially treat or prevent Alzheimer’s is a bold and testable hypothesis that has ignited scientific interest.

For this APOE4/4 carrier, and already beyond the average age of Alzheimer’s onset for many with my genotype - waiting passively for research to “catch up” is not an option. I’ve spent years studying the lithium literature and am comfortable with the risk–benefit profile at very low doses. Based on that work, I take 5–10 mg of lithium orotate nightly, a practice I began a few years ago after reading a 2015 study suggesting lithium’s potential to support cognition. For me, this is not experimentation, it’s an informed, measured decision grounded in science, context, and personal risk tolerance.

Other references:

https://pubmed.ncbi.nlm.nih.gov/19754466/

https://pubmed.ncbi.nlm.nih.gov/29232923/

https://pubmed.ncbi.nlm.nih.gov/?term=lithium+alzheimer%27s

https://www.science.org/content/article/could-lithium-stave-alzheimer-s-disease?

https://www.sciencedirect.com/science/article/abs/pii/S0304394021004225?via%3Dihub

Tolion Health AI is looking for APOE4/4 carriers willing to participate in a short live feedback session to help shape the development of a new app: Tolion Brain Coach.

Tolion was founded by Dr. Martin Tolar, the same physician-scientist behind Alzheon’s ALZ-801, a targeted therapy developed specifically for APOE4-related Alzheimer’s risk.

Tolion is currently gathering feedback on an early version of the app and looking to learn from real experiences within the APOE4/4 community.

Participants who complete a 1-hour video call will receive a $50 Amazon gift card as a thank-you.

If you’re APOE4/4 and interested in contributing to tools being built for our community, you can learn more and sign up here:

https://forms.gle/xz56Hm92x8v1UybdA

In 2023, my HbA1c hovered around 5.5%, just one decimal point shy of being labeled pre-diabetic. That number alone was enough to push me into action. I decided to wear a CGM (continuous glucose monitor) because I wanted to understand what was actually happening beneath the surface - and why, despite what I believed were healthy food choices, my A1C was this high.

What I saw was sobering.

My average glucose was around 110 mg/dL, and foods widely considered “healthy” - apples, bananas, even very modest portions of starch - sent my glucose soaring. Seeing those spikes in real time was a shock. I had no idea how frequently my glucose was being yanked upward, despite what I thought was a careful, whole-food diet.

The Cost of “Doing Everything Right”

By 2025, I managed to bring my average glucose down to about 89 mg/dL (CGM reading below) - but the price was steep.

I achieved those numbers only by becoming extremely restrictive:

• avoiding entire food groups

• eating very little variety

• constantly anticipating spikes

• and, ultimately, losing weight I couldn’t afford to lose

On paper, my metabolism looked much better.
But my 5’7” frame was beginning to look uncomfortably thin as my weight dipped below 120 lbs.

By late summer last year, I made a hard but necessary decision: I would stop trying to improve insulin sensitivity temporarily and focus solely on regaining weight. Being underweight was a more immediate health risk than a borderline A1C.

Letting Go of the CGM (and the Rules)

In August, I stopped using my CGM altogether. I stopped checking finger sticks. I stopped worrying about spikes.

I ate anything I wanted - as long as it was whole food. And yes, I broke some rules. Even Ice cream made a few appearances… So did bread. And during the holidays, I happily worked my way through a huge box of German Christmas treats - Lebkuchen, chocolate-covered pretzels, pralines - sent by a business associate from across the pond.

Not seeing glucose spikes in real time didn’t mean they weren’t happening.
But my priority was clear: restore weight first, worry about A1C later.

What happened next surprised me more than anything I’ve seen in years of health and biometrics tracking.

January 2026: A Stunning Surprise

I hadn’t worn a CGM since mid-2025. I hadn’t checked my A1C since October, when it was still sitting on the cusp. Now that I was close to my weight goal, I decided to put a CGM back on - fully expecting to see damage from five months of relaxed eating.

Instead, I was stunned.

On day one, my glucose stayed steady and low….didn’t peak over 130 mg/dL all day. I was suspicious the CGM was “off” since I expected to see the usual averages. I double-checked this with finger-prick tests - the CGM was accurate. Over the following days, my surprise escalated to something close to disbelief.

My insulin sensitivity had dramatically improved.

Today, my average glucose sits around 90 mg/dL:

• without restriction

• without fear

• without hyper-vigilance

• and without worrying about weight loss

I went from an average glucose of ~118 mg/dL in October to ~90 mg/dL in January.

A bowl of steel-cut oats — which would have spiked me to 170–180 mg/dL last year — now barely reaches 130 mg/dL. My morning glucose, once in the low 90s, is now typically in the low 70s.

What Changed?

Two things - and they likely matter together.

1. Saffron (Yes, Really)

I didn’t discover saffron through a paper or a podcast.

In October, while visiting Turkey, my husband and I wandered into a spice shop in the Grand Bazaar, in Istanbul. The shop owner enthusiastically explained saffron’s benefits - mood, inflammation, vitality - and then casually added:

“It’s a potent spice to regulate insulin.”

That phrase got my attention!

Given how close my A1C was to the prediabetic range, we figured: why not try it? We bought an 8-ounce bottle of saffron threads to take home.

We began drinking a simple daily “tea”:
10–12 saffron threads, steeped in hot (not boiling) water for 20 minutes.

No expectations. No protocol. Just curiosity….and I’d actually forgotten why we were even drinking it!!

2. C8 MCT Oil (The Quiet Enabler)

Around the same time (October 2025), there was one other change to my routine. I began adding one teaspoon of C8 MCT powder to the two cups of morning coffee I drink daily.

C8 doesn’t lower glucose directly. Instead, it provides rapid ketone fuel, reducing reliance on glucose and improving metabolic flexibility. In hindsight, it likely helped stabilize my baseline, flatten curves, and buffer glucose excursions - creating fertile ground for saffron’s effects to shine.

What I’m Seeing Now

Since adding saffron and MCT C8 powder, my glucose response has fundamentally shifted over the last few months - in a way I could only have dreamed of last year.

Foods that once guaranteed spikes - pasta, potatoes, bread, even a chocolate praline - now produce modest, well-contained responses, with faster recovery and smoother curves. Peaks generally stay under 130 mg/dL, often much lower depending on food and combination (order of eating).

Even more remarkable:

• My post-meal glucose reliably drops back under 100 mg/dL within ~90 minutes

• My fasting glucose is now typically in the low 70s

• Overnight glucose is flat and stable

• Overall variability is dramatically reduced

My glucose metabolism is no longer being managed into submission.
It’s doing what it’s supposed to do again. This is metabolic resilience and I’m delighted it found me entirely by chance in an Istanbul spice bazaar.

How Might Saffron Be Doing This?

• Improved insulin sensitivity
  Saffron’s bioactive compounds (notably crocin and safranal) appear to enhance GLUT4 translocation, improving glucose uptake in skeletal muscle.

• Reduced stress-mediated glucose release
  Saffron influences stress and cortisol signaling - critical, because stress alone can drive post-meal glucose elevations.

• β-cell protection
  Evidence suggests saffron reduces oxidative stress on pancreatic β-cells, potentially improving first-phase insulin response.

• Central glucose regulation
  Saffron also acts in the brain, influencing glucose sensing and appetite signaling - an often-overlooked layer of glucose control.

A Final Word

Everyone responds differently.
This is N=1

But I would be remiss not to share something that has been genuinely life-changing for me.

Maybe saffron is under-explored simply because of its cost in the U.S. I don’t know. What I do know is that I’ll be eternally grateful to a spice merchant in Istanbul who insisted I take some home.

When I put on a CGM a few weeks ago, I had almost forgotten about him - until I found myself scrambling for an explanation as to why my average glucose dropped so obviously and dramatically - despite breaking all my usual dietary rules for months!

Sometimes the biggest shifts come from the least expected places.

Nature is a beautiful thing and yes, plants can be the most effective medicine!

Disclaimer:
This is my personal, N=1 experience and not medical advice. Responses to saffron, C8 MCT oil, and dietary changes can vary significantly between individuals. Those with diabetes, reactive hypoglycemia, eating disorders, or who use glucose-lowering medications should consult a qualified healthcare professional before making changes.

That structure is lipids.

This topic has become central in my own efforts to silence the expression of my APOE4/4 genes, not by chasing single targets, but by supporting the structural foundation that everything else depends on.

Why Lipids Matter More Than They Get Credit For

Every cell in the body is enclosed by a phospholipid bilayer. Inside each cell, mitochondria - our energy engines - are also wrapped in highly specialized lipid membranes.

These membranes determine:

• how nutrients enter the cell

• how waste products leave

• how receptors respond to hormones and neurotransmitters

• how efficiently mitochondria produce ATP

• how much oxidative stress and inflammation accumulate

When membrane lipids are damaged, depleted, or replaced with inferior substitutes, cellular function degrades - even when standard lab values appear “normal.”

This is especially relevant for those of us with APOE4, a genotype known for inefficient cholesterol efflux. That reality naturally leads to a deeper question: what is actually controlling cholesterol movement at the cellular level?

Cholesterol Doesn’t Simply “Leave” a Cell

Cells don’t dump cholesterol into the bloodstream on their own.

Cholesterol exits cells through active export systems embedded in the cell membrane, primarily transporters such as ABCA1 and ABCG1. These transporters:

• sit within the lipid bilayer

• require a fluid, well-composed membrane to function

• load cholesterol onto lipid-poor particles such as HDL or ApoE

So cholesterol efflux isn’t just about how much cholesterol is inside a cell -
it’s also about the condition of the membrane it must pass through.

ABCA1: A Quiet but Critical Player in Alzheimer’s Risk

One of the lesser-discussed contributors to Alzheimer’s risk - particularly for APOE4 carriers - is ABCA1, a transport protein responsible for moving cholesterol out of cells and properly lipidating ApoE particles.

When ABCA1 function is suboptimal:

• cholesterol lingers inside neurons and glial cells

• membranes become stiffer

• ApoE (already less efficient in APOE4) becomes poorly lipidated and more inflammatory

Importantly, this is rarely an “on/off” genetic defect. It’s usually a matter of efficiency.

ABCA1 activity appears to be supported by:

• healthy membrane composition

• adequate phospholipid availability

• good mitochondrial function

• regular physical activity

• metabolic flexibility

• lower chronic inflammation

In other words, cholesterol trafficking is not just a lab-number issue - it’s structural and functional.

Why Membrane Composition Matters So Much

Cell membranes aren’t passive barriers. They are working surfaces.

Their ability to move cholesterol depends on:

• membrane fluidity

• proper phospholipid balance

• intact lipid raft structure

• healthy mitochondrial and ER membranes

If membranes become:

• rigid

• oxidized

• depleted of key phospholipids

then cholesterol export becomes inefficient even when transport proteins are present.

It’s like having delivery trucks waiting at a loading dock with no staff to unload. The system exists - but nothing moves smoothly.

Where APOE4 Complicates the Picture

APOE4 introduces several overlapping vulnerabilities:

1. Poor ApoE Lipidation

APOE4 forms less well-lipidated ApoE particles, meaning cholesterol has fewer high-quality carriers and lingers longer inside cells.

2. More Rigid, Cholesterol-Dense Membranes

APOE4 brains tend to show:

• higher membrane cholesterol content

• altered lipid raft structure

• reduced membrane fluidity

Rigid membranes translate into sluggish transporter function.

3. Structural Stress on ABCA1

ABCA1 does not operate in isolation. It depends on:

• adequate phosphatidylcholine

• sufficient plasmalogen content

• intact membrane curvature and flexibility

When membranes are phospholipid-poor or oxidatively damaged, ABCA1 efficiency drops - even if the gene itself is active.

Why This Matters Especially for the Brain

Neurons and glial cells:

• synthesize their own cholesterol

• rely heavily on local recycling and efflux

• tolerate cholesterol accumulation poorly

When efflux falters:

• synaptic membranes stiffen

• receptor signaling degrades

• inflammation rises

• amyloid processing shifts in an unfavorable direction

This helps explain why APOE4 brains can show pathology even without markedly elevated blood cholesterol. It’s a cellular trafficking problem, not simply a serum lipid issue.

Where Phospholipids and Plasmalogens Fit In

Without overreaching beyond the data, the logic is straightforward:

• Phosphatidylcholine provides structural material for ApoE and HDL particles

• Plasmalogens support membrane fluidity and antioxidant defense

• Healthier membranes improve transporter performance

• Better transporter performance improves cholesterol efflux

• Improved efflux reduces intracellular cholesterol stress in neurons

This doesn’t “fix” APOE4 - but it may well reduce one of its most important structural bottlenecks.

Where Dietary Fats Quietly Reinforce This Framework

Alongside targeted phospholipid support, I think it’s important not to overlook the quieter, foundational role of dietary fats that integrate into membranes over time. Extra virgin olive oil provides monounsaturated fats and polyphenols that support membrane fluidity while reducing oxidative stress within the lipid bilayer, particularly in neuronal and mitochondrial membranes. In parallel, supplemental omega-3s - with an emphasis on DHA - supply a fatty acid that is structurally essential for synaptic membranes, lipid rafts, and mitochondrial efficiency. DHA is not simply a signaling molecule; it is a literal building block of neuronal architecture. Taken consistently, these fats don’t replace Lipid Replacement Therapy, but they help ensure that when phospholipids and plasmalogens are supplied, they are incorporated into a membrane environment that is flexible, resilient, and less prone to inflammatory signaling.

Why Pulsing Lipid Support Makes Sense

Efflux systems don’t benefit from constant stimulation.
They benefit from repair, followed by time to function normally.

How I Personally Think About LRT (as APOE4/4)

I don’t use Lipid Replacement Therapy because I’m chasing perfection or trying to micromanage biology.

Because I’m APOE4/4, I know my brain depends heavily on healthy lipids — and I also know lipid handling isn’t always efficient or forgiving. My goal isn’t to push lipids constantly, but to ensure I’m not quietly missing important building blocks over time.

How I Use It, in Plain Terms

I use phosphatidylcholine as the base, specifically BodyBio PC, (*use code APOE4 for a discount) because it’s clean, gentle, and after using it for several years, I trust the brand!

I take it with meals, split across the day, without obsessing over dose. I’m simply supplying raw material during periods when I’m intentionally supporting membrane structure.

At times, I layer in plasmalogens, using Prodrome Glia and Prodrome Neuro. I think of these as more brain-specific lipids - especially relevant as plasmalogen levels decline with age and appear tied to Alzheimer’s risk.

I don’t take these continuously. I use / pulse them intentionally.

The Rhythm That Feels Right to Me

My pattern is simple:

• several weeks on (PC plus plasmalogens)

• several weeks off, with no lipid-specific supplementation

During the “on” phase, I support structure.
During the “off” phase, I let the system integrate and function.

That rhythm feels far more biologically appropriate than constant daily input.

One very simple, low-effort addition I rely on to support Lipid Replacement Therapy is eating small fatty fish - usually sardines or mackerel - about three times per week. I’ll be honest: sardines aren’t everyone’s favorite, so I often make them into patties, which makes them far more appealing without the fishy taste. I think of this as a practical safety net. Because DHA and EPA need to be incorporated into cell membranes over time, getting them regularly from whole food provides a buffer in case absorption from supplements is imperfect or inconsistent, especially in a genotype where lipid trafficking is already less efficient. Given how central membrane integrity is to mitochondrial function, lipid trafficking, and synaptic resilience, this is an easy, sustainable habit that quietly reinforces the goals of Lipid Replacement Therapy without requiring precision or perfection.

A note for sterol hyperabsorbers:

A subset of individuals - including some APOE4 carriers - are sterol hyperabsorbers, meaning they absorb plant sterols more efficiently through NPC1L1. In these cases, foods rich in phytosterols (such as nuts, seeds, and certain plant oils) can raise circulating plant sterols and potentially contribute to arterial or cellular sterol burden. This does not negate the importance of membrane integrity or lipid replacement, but it does mean that fat selection matters. For sterol hyperabsorbers, focusing on low-sterol fat sources while supporting phospholipids, DHA, and membrane structure can help align lipid replacement goals with individual absorption biology. There is one test I’m aware of that clearly identifies sterol absorption status: the Boston Heart Diagnostics Cholesterol Balance Test. It measures cholesterol production markers (desmosterol and lathosterol) alongside absorption markers (beta-sitosterol and campesterol). For many years I consumed large amounts of flaxseed, believing it was beneficial - only to later discover that I am a sterol hyperabsorber and need to avoid foods high in plant sterols. In that context, Ezetimibe (Zetia), which blocks intestinal sterol absorption, has been particularly helpful.

Where Statins Fit in a Lipid Replacement Framework

A brief note on statins is warranted here, because Lipid Replacement Therapy is often misunderstood as being “anti-statin.” That is not how I think about it. As I discussed in a previous postprimarily reduce circulating cholesterol synthesis and particle burden, while LRT focuses on restoring membrane composition, mitochondrial integrity, and lipid trafficking at the cellular level. These are not redundant targets. In an APOE4 context, lowering inflammatory lipid flux in the bloodstream and improving the quality and resilience of cellular membranes can be complementary strategies rather than competing ones. Linking the two helps move the conversation away from ideology and toward systems-level biology.

Final Thought

For me, Lipid Replacement Therapy is about respecting structure.

Healthy membranes don’t guarantee cognitive longevity - but without them, everything else has to work harder than it should. Pulsing phosphatidylcholine and plasmalogens feels like a reasonable, measured way to ensure my brain isn’t quietly short on the materials it depends on most.

Disclaimer

This content is for educational and informational purposes only and reflects my personal research, my interpretation of scientific literature, and my individual experience. It is not intended as medical advice, diagnosis, or treatment, and should not be used as a substitute for professional medical care.

Discussions of Lipid Replacement Therapy (LRT), phosphatidylcholine, plasmalogens, APOE genotype, cholesterol metabolism, ABCA1, or related mechanisms are theoretical and evolving. While grounded in current research, many concepts described are based on mechanistic reasoning, preclinical data, or limited human studies, and definitive clinical outcomes are not established.

It was clearly associated with Alzheimer’s disease, the strongest genetic risk factor we know, yet the why remained frustratingly vague. APOE4 was treated as probabilistic destiny rather than actionable biology. I carry it. I worried. I hoped answers would emerge before it was too late.

Across the last several years, and accelerating recently, a much clearer picture has emerged. Not from one dramatic study, but from converging lines of evidence that all point in the same direction:

APOE4 actively disrupts lipid trafficking and lipid metabolism in the brain.

And that disruption appears to sit upstream of inflammation, synaptic failure, amyloid accumulation, and tau pathology.

This is not semantics. It’s a fundamental shift in how Alzheimer’s risk is understood, and how it should be addressed.

What is now crystallizing across the science

Independently, multiple research groups studying astrocytes, microglia, neurons, lipid and mitochondrial metabolism have arrived at overlapping conclusions:

• APOE4 alters how lipids are transported between brain cells
• Support cells accumulate lipids instead of efficiently using or delivering them
• Fatty acids are stored in lipid droplets rather than oxidized
• Mitochondrial lipid metabolism becomes impaired
• Inflammatory signaling increases.
• Neurons lose access to the structural lipids they depend on

Critically, these changes appear early, well before cognitive symptoms, and they occur independent of amyloid plaques.

Amyloid and tau still matter. But they increasingly look like downstream accelerants, not the original failure.

The original failure appears to be metabolic and structural.

Why lipid trafficking matters so much

Neurons are unusually dependent cells.

They do not make their own cholesterol or phospholipids in meaningful amounts. They rely on astrocytes and microglia to deliver the lipids required for:

• synaptic membranes
• mitochondrial membranes
• myelin maintenance
• dendritic remodeling
• membrane repair

When lipid delivery falters, neurons don’t immediately die …. they degrade. Synapses weaken. Energy falters. Plasticity declines. Vulnerability increases.

From this perspective, Alzheimer’s looks less like a protein aggregation disorder and more like a chronic failure of cellular maintenance and lipid logistics.

APOE4 doesn’t merely increase risk, it changes how the system operates.

The only logical response: intervene upstream

If the core vulnerability is impaired lipid handling, then prevention cannot revolve solely around plaque clearance or late-stage rescue attempts.

The rational strategy becomes:

Support lipid transport
Protect membrane integrity
Improve lipid utilization
Reduce inflammatory lipid signaling
Preserve metabolic and circadian stability

This reframes prevention from fear-driven restriction to active systems support.

Share

How I’m responding practically, not theoretically

I am APOE4/4. I’m not interested in abstract reassurance. I want biological leverage.

1. Supporting membrane integrity deliberately

APOE4 delivers lipids poorly. That means membranes age faster.

I focus on rebuilding and maintaining membrane composition, particularly phospholipids critical for neuronal and mitochondrial health. It’s about structural maintenance.

2. Preventing toxic lipid accumulation

The problem is not fat, it’s fat that can’t be processed.

So, I prioritize:
• mitochondrial support
• fatty-acid utilization
• metabolic flexibility
• resistance training

When lipids are oxidized properly, they don’t accumulate pathologically in glial cells.

3. Stabilizing gut–brain lipid signaling

Peripheral inflammation worsens central lipid dysfunction.

I’ve focused on restoring gut barrier integrity and short-chain fatty acid signaling, not as a digestive project, but as neuroinflammatory control.

4. Protecting sleep as a biological process

Sleep is when the brain clears lipids and repairs membranes.

Fragmented sleep undermines lipid trafficking via the glymphatic system. I treat deep sleep as non-negotiable neuroprotection, not just “nice to have”.

5. Avoiding known APOE4 stressors

Some exposures matter more when lipid handling is fragile:

• chronic glucose volatility
• inflammatory overload
• sterol excess
• hormonal instability

Why this approach feels different

This approach is responding to what the research is clearly telling us.

When multiple independent fields converge on the same mechanism, the prudent move is not to wait for perfect consensus, it is to act intelligently on the emerging signal.

My Conclusion

APOE4 is not destiny, but it is instruction.

Research tells us where the system is fragile.
It tells us what appears to break first.
And increasingly, it points to ways, how to intervene.

By focusing on lipid trafficking, membrane integrity, and metabolic stability, we are no longer guessing. We are working with the biology instead of reacting to its failure.

That shift - from risk management to systems support - may be the most important evolution in Alzheimer’s prevention we’ve seen in decades.

And for those of us carrying APOE4, it finally gives us a plan. Stay tuned for my next post, which will discuss LRT … Lipid Replacement Therapy.

Share

Senescent cells are cells that have exited the cell cycle but refuse to die. They are often referred to as “zombie cells”. Instead, they secrete a potent mix of inflammatory cytokines, proteases, and growth factors — the senescence-associated secretory phenotype (SASP) — which damages surrounding tissue and amplifies inflammation.

For APOE4 carriers, this matters disproportionately.

In the brain, senescent cells have been identified in astrocytes, microglia, endothelial cells, and oligodendrocyte lineage cells — precisely the cell types already vulnerable in APOE4 brains. These cells govern neuroinflammation, vascular integrity, metabolic support, and synaptic health, all of which tend to show earlier dysfunction in APOE4 carriers

Why APOE4 Requires a Different Strategy

APOE4 biology is characterized by:

• Higher baseline inflammation

• Chronically primed microglia

• Earlier blood–brain barrier vulnerability

• Greater sensitivity to immune, thyroid, and mitochondrial suppression

This means that strategies tolerated by the general population could backfire when applied continuously in APOE4 carriers.

Senolytics are a perfect example.

They are powerful tools — but they are not meant to be taken every day.

For APOE4 carriers, indiscriminate or continuous senolytic pressure risks disrupting immune surveillance, thyroid signaling, and mitochondrial resilience — systems that are already more fragile.

The Study That Changed the Alzheimer’s Conversation

One of the most influential studies in this field demonstrated that clearing senescent astrocytes and microglia in a tau mouse model reduced tau pathology and preserved cognitive function.

This does not prove human prevention. But it strongly suggests that senescent glial cells are active contributors to neurodegeneration rather than innocent bystanders — a finding with particular relevance for APOE4 brains that enter inflammatory and vascular stress states earlier.

My Experience With Potent Senolytics (and Why It Shaped My Approach)

Under the guidance of the late Dr. Alan Green, Dasatinib was discussed and prescribed for me as part of a senolytic strategy to follow. Despite extensive research prior to taking the first dose, and taking only half of the prescribed dose, I experienced significant side effects…. including a clear episode of tachycardia — unmistakable physiologic disruption along with significant nausea and strong headache.

It reinforced several truths:

• Dasatinib is a potent oncology drug, not a nutraceutical

• Individual sensitivity varies widely

• Even “low” doses can have systemic effects

• Strong Senolytics are not something to experiment with casually

To reduce side effects, I later broke the dose into smaller fractions (+/- 25 mg) staggered over the day in minimum 6 hour increments, maintaining exposure while avoiding excessive peak levels. Even so, the experience solidified my conviction: respect the biology, respect the drug, and err on the side of caution.

Why I Do Not Take Senolytics Daily

Senescent cells accumulate slowly. They do not require daily pressure.

Daily senolytics can:

• Blunt hormetic signaling

• Interfere with thyroid hormone transport

• Suppress immune surveillance

• Disrupt mitochondrial signaling

Instead, I follow the logic used in most animal models and early human studies:

Short pulses, followed by long recovery periods.

The Senolytics I Use

My core senolytics are:

• Quercetin

• Fisetin

  
  They target overlapping but not identical senescent cell populations, providing broader coverage without aggressive dosing.

• An additional 100 mg Dasatinib total, micro-dosed over 24-36 hours during pulse periods only, to extend coverage without increasing peak exposure

This micro-dose is never taken daily and never outside pulse windows.

My Annual APOE4/4 Senolytic Calendar

Monthly Maintenance Pulses (8× per year)

January · February · April · May · July · August · October · November

• Duration: 2 consecutive days

• Each day:

  • Quercetin: 1,000 mg

  • Fisetin: 1,000–1,500 mg

• Added micro-dose (first day only):

  • 100 mg Dasatinib total, split into 25 mg × 4 doses

  • Morning · Midday · Late afternoon · Early evening

  • I skip the Dasatinib bedtime dosing if I am experiencing any unpleasant side effects and take the next morning.

Purpose:
Maintenance clearance — preventing senescent immune and glial cells from re-establishing a chronically inflamed baseline. It’s worth noting that Quercetin and Fisetin are both fat soluble so need to be taken with fat.

Quarterly Deep Reset Pulses (3× per year)

March · June · September

• Duration: 4 consecutive days

• Each day:

  • Quercetin: 1,000 mg

  • Fisetin: 1,500–2,000 mg

• Same micro-dose:

  • 100 mg Dasatinib total over 24 hours, split into 4-5 increment doses

I do not increase beyond this.

Purpose:
Broader systemic and CNS-adjacent senescent clearance, particularly relevant for aging microglia and endothelium.

Mandatory Senolytic Rest Month

December

• No quercetin

• No fisetin

• No Dasatinib micro-dose

• No other senolytics or aggressive polyphenols

This rest period matters. It allows immune surveillance, hormetic signaling, thyroid transport, and mitochondrial pathways to fully reset.

Guardrails I Consider Non-Negotiable

• I never overlap senolytic pulses with rapamycin (minimum 4 days apart)

• I space senolytics several hours away from thyroid medication

• I avoid stacking additional polyphenols on pulse days

• I do not fast aggressively or perform intense HIIT during pulses

How I Know It’s Working

I don’t expect fireworks during pulse days. Benefits show up weeks later, not immediately.

What I watch:

• hs-CRP trends

• Sleep depth and HRV

• Cognitive clarity

• Subtle inflammation markers

Quiet, cumulative improvement beats dramatic short-term effects.

Final Thoughts

This is my personal protocol, shaped by:

• APOE4/4 biology

• Inflammation sensitivity

• Thyroid considerations

• Mitochondrial health

• Long-term sustainability

I believe senolytics should feel like spring cleaning, not daily housekeeping.

Disclaimer

This post is for educational purposes only and does not constitute medical advice. It’s what I do, and what I know works for my body! Dasatinib is a prescription medication with significant risks and should only be used under medical supervision.

Is Botox safe if you’re APOE4 positive?
Short answer: from everything I’ve read in extensive research for my own peace of mind: yes.

Long answer below, with nuance.

Why this question comes up for APOE4 carriers

APOE4 carriers are rightly cautious. We’re taught—correctly—that APOE4 is associated with:

• Increased neuroinflammation

• Greater blood–brain barrier (BBB) vulnerability

• Altered lipid transport and neuronal repair

So when something with the word “toxin” is injected anywhere near the head or face, it’s very reasonable to ask whether it could have downstream neurological effects.

The good news is that cosmetic Botox does not intersect with APOE4 biology in any meaningful way.

What Botox actually does (and does not do)

Botox is a purified form of botulinum toxin type A, used in very small, localized doses for cosmetic purposes (e.g., frown lines).

Mechanistically:

• Botox acts peripherally, at the neuromuscular junction

• It blocks acetylcholine release locally, preventing muscle contraction

• It does not circulate systemically in meaningful amounts

• It does not cross the blood–brain barrier

This is crucial.

I have not found any plausible biological pathway by which cosmetic Botox could affect brain tissue, amyloid, tau, ApoE metabolism, or neuroinflammation.

What the data show

Botox has been used cosmetically for over 20 years, with tens of millions of injections worldwide.

Across that time:

• There has been no signal of increased dementia risk

• No association with cognitive decline

• No evidence of neurodegenerative disease acceleration

• No APOE-stratified signal suggesting harm

If cosmetic Botox meaningfully increased Alzheimer’s risk, it would have shown up by now. It hasn’t.

APOE4-specific concerns addressed directly

Let’s address the usual worries head-on:

Blood–brain barrier issues?

Botox does not cross the BBB.

Neurotoxicity?

At cosmetic doses, Botox remains localized and peripheral.

Inflammation?

Botox does not activate inflammatory pathways relevant to Alzheimer’s disease.

ApoE interaction?

None. Botox does not interact with lipid transport, amyloid processing, or ApoE signaling.

From an APOE4 standpoint, Botox is biologically irrelevant to Alzheimer’s risk.

An interesting (but not preventative) side note

There is some speculative research suggesting that reducing chronic frowning may:

• Modulate emotional feedback loops

• Slightly reduce stress reactivity

This is not an Alzheimer’s prevention strategy, but chronic stress is harmful to APOE4 brains—so at worst, Botox is neutral; at best, it may modestly reduce stress signaling.

This is a side note, not a recommendation.

When caution is warranted (not APOE4-specific)

Botox should be avoided or carefully considered if you have:

• Neuromuscular disorders (e.g., myasthenia gravis)

• Rare systemic reactions to botulinum toxin

• Very high cumulative therapeutic doses (not cosmetic)

These concerns apply to everyone, not APOE4 carriers specifically.

Bottom line

• Cosmetic Botox (e.g., frown lines) appears safe for APOE4 carriers

• There is no evidence it increases Alzheimer’s risk

• It does not interact with ApoE biology

• Cognitive protection efforts are better focused on sleep, vascular health, metabolic control, and inflammation

A recent Advanced Science study reported that repeated exposure to botulinum neurotoxin A (BoNT/A) in a laboratory neuron-glia culture model triggered inflammatory changes and neuronal stress signals in that model system. PubMed It’s important to understand what this does and doesn’t mean: the study used direct, repeated exposure in a simplified cell system, not tiny cosmetic doses injected into a facial muscle. Laboratory models help scientists explore mechanisms under controlled conditions, but they do not show that Botox injections at clinical cosmetic levels cause neuroinflammation or neurodegeneration in humans. Over two decades of real-world cosmetic use have not produced evidence of increased dementia or Alzheimer’s risk from cosmetic Botox.

A quick note on fillers: unlike Botox, dermal fillers add volume and leave material in the tissue for extended periods. There is no evidence that cosmetic fillers increase Alzheimer’s risk or interact with APOE4 biology. However, fillers carry local, cumulative tissue risks—particularly with repeated use and advancing age—and they often do not age well over time. For this reason, while Botox is largely biologically neutral and reversible, fillers warrant a more cautious, individualized discussion focused on long-term tissue health rather than brain risk. Personally, I draw the line with putting any substance into my body that stays there for a very long time or permanently.

Further Reading (PubMed / Scientific Sources):

• Safety of Botulinum Toxin Type A — Systematic Review (PubMed): https://pubmed.ncbi.nlm.nih.gov/15265242/

• The Whole Truth About Botulinum Toxin (NIH review): https://pubmed.ncbi.nlm.nih.gov/31410104/

• Botulinum Toxin — NCBI Bookshelf Review: https://www.ncbi.nlm.nih.gov/books/NBK557387

Additional Research and Context:

• BOTOX & Learning/Memory in Mice: https://pubmed.ncbi.nlm.nih.gov/32974763/

• Pilot Trial of Incobotulinumtoxin A in Dementia: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275182/

• Botulinum Toxin Type A Effects in Parkinson’s: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129423/

General Safety Summaries:

• Healthline overview of neurological side effects: https://www.healthline.com/health/drugs/botox-neurological-side-effects Healthline

• Cleveland Clinic on long-term effects: https://health.clevelandclinic.org/long-term-effects-of-botox Cleveland Clinic

Alzheimer’s disease is not a single biological process, and genetic risk does not express itself uniformly. APOE4 is the most common genetic risk factor for late-onset Alzheimer’s disease, but its impact is often misunderstood because it does not simply accelerate the same pathways seen in non-carriers.

It’s also worth noting that rapamycin has become one of the most actively studied and discussed compounds in the field of aging biology. Across multiple species, rapamycin has consistently been shown to extend lifespan and, more importantly, healthspan, making it a central focus of modern anti-aging research. While longevity and neurodegeneration are often discussed separately, this distinction may be artificial. Alzheimer’s disease is, by definition, a disease of aging.

If a therapy meaningfully slows the biological processes of aging itself - particularly those involving cellular stress, metabolic dysfunction, inflammation, and vascular decline - it follows that such an intervention could also delay, or reduce the risk of, age-associated diseases, including Alzheimer’s disease. This does not prove prevention, but it provides a coherent biological rationale for why rapamycin continues to attract attention as a candidate intervention in Alzheimer’s prevention research.

APOE4 alters brain biology early - affecting cerebral blood flow, glucose metabolism, blood–brain barrier integrity, and neuroinflammatory tone - often decades before symptoms appear. This has important implications for how and when prevention strategies should be evaluated.

Which raises a simple question:

If APOE4 biology diverges early, what protective strategies can we employ before advancing age places us at heightened risk?

This is where rapamycin enters the conversation.

What Rapamycin Is - and What It Is Not

Rapamycin (sirolimus) is an FDA-approved drug that has been used for decades, originally at high, continuous daily doses in organ transplant medicine for immunosuppression.

The interest in rapamycin for aging and neurodegeneration is very different.

At low and intermittent doses, rapamycin acts primarily as a modulator of the mTOR (mechanistic target of rapamycin) pathway - a central regulator of cellular growth, metabolism, autophagy, immune tone, and vascular function.

Importantly, rapamycin behaves differently across genotypes. In mouse studies, its effects differ in E3/FAD versus E4/FAD models (FAD = mice bred to develop familial Alzheimer’s disease), underscoring that APOE genotype matters.

The off-label use of rapamycin is not fringe science. mTOR signaling sits at the crossroads of nearly every process that goes awry in aging brains.

What remains controversial is the idea of using rapamycin preventively, especially in cognitively normal individuals at genetic risk for Alzheimer’s disease.

That controversy deserves careful examination - not dismissal.

In the linked video, Dr. Matt Kaeberlein, PhD, explains rapamycin and its potential relevance to APOE4-mediated Alzheimer’s prevention.

Why mTOR Matters - Especially for APOE4

APOE4 brains do not age gracefully.

Long before plaques and tangles dominate pathology, APOE4 carriers commonly exhibit:

• Reduced cerebral blood flow

• Impaired glucose metabolism (brain hypometabolism)

• Increased neuroinflammation

• Greater blood–brain barrier permeability

• Reduced synaptic resilience

These changes often begin in midlife or earlier.

mTOR overactivation is implicated in each of these processes.

In animal models of Alzheimer’s disease, mTOR inhibition has repeatedly been shown to:

Improve autophagy and cellular cleanup

• Reduce neuroinflammatory signaling

• Improve vascular function and cerebral blood flow

• Restore aspects of learning and memory

• Reduce amyloid and tau pathology when intervention occurs early

What is especially relevant for APOE4 carriers is that rapamycin appears to improve vascular and metabolic function - the very domains that fail first in APOE4 brains.

This is why many researchers believe that if rapamycin has a role in Alzheimer’s disease, it is most likely as a preclinical or early intervention, not a late-stage treatment.

Animal Studies Are Compelling - but Not Enough

Let’s be clear: animal studies do not prove human prevention.

But they do establish biological plausibility.

Across multiple Alzheimer’s models, rapamycin and other mTOR inhibitors have shown benefits when administered before or early in disease progression. When given too late - after substantial plaque and tangle burden - benefits are often diminished, absent or accelerated.

This timing issue matters enormously for APOE4 carriers, whose pathological trajectory tends to begin earlier than that of non-carriers.

What About Humans?

Human data are still early - and that matters.

To date, we do not have completed randomized controlled trials showing that rapamycin prevents Alzheimer’s disease in humans.

What we do have includes:

• Phase 1 and feasibility trials demonstrating that rapamycin can be safely administered in older adults and reach relevant biological compartments

• Ongoing and registered trials examining cognitive and biomarker outcomes in mild cognitive impairment and early Alzheimer’s disease

• Growing interest in genotype-specific responses, including APOE stratification

In other words, the science is not settled - but it is very much in motion.

A Clinical Pioneer: Dr. Alan Green

No discussion of rapamycin and APOE4 would be complete without acknowledging Dr. Alan Green, MD, of Little Neck, New York - one of the earliest physicians to advocate for off-label rapamycin use in longevity and Alzheimer’s prevention.

Dr. Green repeatedly described APOE4 carriers as one of the most neglected patient populations in medicine, and he structured much of his practice around mitigating their risk. I had the pleasure and privilege of being one of his patients.

In conversations prior to his death in 2024, Dr. Green told me he had treated over 500 APOE4 carriers, including many homozygotes, with low-dose rapamycin - and that to his knowledge, none had developed Alzheimer’s disease while under his care.

This was a striking, hypothesis-generating clinical observation - one that helped facilitate my personal decision to start rapamycin and more deeply research the topic.

My Own Experience (and Why I Share It)

As a patient of the late Dr. Green, I’ve been on rapamycin since 2021.

When I learned of my APOE4 status, I was already at the average age of disease onset for women with my genotype. I was resolute in my desire to change that trajectory and willing to take a calculated risk to do so.

I’ve experienced no side effects. My dose is 6 mg once weekly, and I occasionally skip a week to allow for complete washout.

I share this not as proof, but because prevention discussions often lack real human context - especially among APOE4 carriers who are otherwise told to “wait and see.”

Waiting is not a neutral act when your biology is already diverging.

When Might Rapamycin Make Sense - If at All?

This is where nuance matters.

Based on current evidence, if rapamycin is protective against Alzheimer’s disease, it is most likely to be:

• Preventive or very early, not late-stage

• Considered in midlife or early preclinical stages

• Used after foundational interventions are in place

Rapamycin (sirolimus) hits three pathways that matter a lot for APOE4:

1. mTOR suppression → improved autophagy

• APOE4 brains show impaired clearance of damaged proteins (amyloid, tau, dysfunctional mitochondria).

• mTOR inhibition restores autophagy, which is one of the most conserved longevity mechanisms across species.

• In multiple APOE4 mouse models, rapamycin:

  • Reduces amyloid burden

  • Improves cerebral blood flow

  • Preserves BBB integrity

  • Improves learning and memory

Mechanistically, this is very strong.

2. Neurovascular + BBB protection

This is huge for APOE4.

Rapamycin:

• Improves endothelial function

• Reduces vascular inflammation

• Restores nitric oxide signaling

• Protects pericytes (key for BBB integrity)

This directly targets the APOE4 weak point.

3. Systemic aging signal reduction

Rapamycin is still:

• The most reproducible lifespan-extending drug in mammals

• Effective even when started late in life

• Strongly anti-inflammatory (via immune recalibration, not blanket suppression at low intermittent doses)

Since Alzheimer’s risk rises exponentially with biological aging, this matters.

Rapamycin is not a substitute for foundational support.

Those foundations are non-negotiable:

• Sleep

• Exercise

• Blood pressure control

• ApoB / lipid management

• Insulin sensitivity

• Inflammation control

Risks, Tradeoffs, and Honesty

Rapamycin is not benign.

Potential risks include:

• Mouth ulcers (canker sores)

• GI symptoms

• Impaired wound healing

• Increased infection risk (dose-dependent)

• Metabolic effects in some individuals

• Drug–drug interactions

Anyone considering rapamycin should do so with medical supervision and appropriate monitoring. While I had a canker sore after my first dose in 2021, it resolved in a couple of days and have not had the issue again. I’ve had no other side effects. After Dr. Green’s passing, my primary care physician has continued to prescribe and monitor my rapamycin use. She is aware of my genetic risk and my 4 year history under Dr. Green’s care.

My Take:

For APOE4 carriers, rapamycin is one of the most mechanistically coherent pharmacologic candidates we currently have - particularly for addressing the vascular and metabolic dysfunction that appears early and drives downstream pathology. Yet, it’s important to note:
- It is not proven.
- It is off-label.
And it deserves serious, genotype-informed clinical trials, not dismissal.

The question is no longer whether we should intervene early - but whether we are willing to study early intervention with the urgency this risk demands.

Disclaimer

This post is for educational purposes only and does not constitute medical advice. Rapamycin is an FDA-approved medication used off-label in this context. Decisions about its use should be made with a qualified healthcare provider.

Selected Rapamycin & APOE4-Related Studies:

1. APOE4 impairs autophagy and Aβ clearance by microglial cells

2. Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

3. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease

4. mTOR: Alzheimer’s disease prevention for APOE4 carriers

5. Rapamycin as a preventive intervention for Alzheimer’s disease in APOE4 carriers: Targeting brain metabolic and vascular restoration

6. Neurodegeneration Reversed with mTOR Inhibitor Drug in New Alzheimer’s Study

For more information on Rapamycin, specifically as it relates to its longevity/anti-aging use, can be found at www.rapamycin.news

There may be no topic in the APOE4 community more polarizing than statins.
Some swear them off as if they’re poison; some believe statins are a hoax of big Pharma to line their pockets, and others panic at the idea of taking one.

Let’s cut through the chase:

If you are APOE4 - especially 4/4 - the best available data now shows you may be the group that gains the most brain protection from statins.

This isn’t dogma.
It’s 2024-2025 human data - large, well-controlled studies with genotype-specific results. And their conclusions run directly counter to the internet myths I see recycled endlessly.

Let’s walk through what the research actually says.

Fact: APOE4 carriers show the largest reduction in Alzheimer’s risk after starting a statin.

The pivotal 2024 study published in Neurology looked at 4,807 older adults, tracking who developed Alzheimer’s disease (AD) and how quickly cognition declined.

Here’s the headline:

APOE4 carriers who initiated a statin had a 40% lower risk of developing Alzheimer’s.

• APOE4 carriers: HR 0.60 (95% CI 0.49–0.74)

• Non-carriers: HR 0.96 (no clear benefit)

In other words:

The benefit was exclusive to APOE4 carriers.
Non-carriers saw essentially no change.

And it wasn’t just diagnosis:

APOE4 carriers also had slower decline in global cognition and episodic memory after starting statins.

This is the strongest genotype-specific human evidence we’ve ever had on this question. It directly dismantles the myth that “statins harm the E4 brain.”

Fact: Human data keeps showing a reduction in cognitive decline for APOE4 carriers on a statin.

A 2022 review in Frontiers in Aging Neuroscience examined multiple high-quality studies:

• The Xuan 2020 meta-analysis found that statins preserved cognition more strongly in APOE4 carriers, especially those with high cholesterol.

• The Sydney Memory & Aging Study (Samaras et al., 2019) found that:

  APOE4 carriers using statins had significantly slower cognitive decline over 6 years

  Non-carriers showed no meaningful difference.

• Another cohort (Dagliati et al., 2020) reported that only APOE4-carrier statin users had lower AD/dementia risk.

If statins caused cognitive problems in E4s, these studies would not look like this.

But they do, and consistently.

Fact: APOE4 dramatically increases cardiovascular risk, and statins blunt that risk.

This part of the conversation is often strangely ignored in APOE4 circles.

APOE4 carriers have higher rates of:

• coronary artery disease

• myocardial infarction

• ischemic & hemorrhagic stroke

• endothelial dysfunction

• sterol hyperabsorption (extra LDL load)

This is not theoretical - it’s well established in 20+ years of lipid and epidemiological research. It wasn’t until I took the Boston Heart Lab test, that I found out I’m a major sterol and cholesterol hyper-absorber, as are many other APOE4/4s who might be oblivious to the fact.

Statins reduce LDL-C by 30–50%, which in randomized trials translates into:

• ~60% fewer major cardiovascular events

• ~17% lower stroke risk

APOE4 carriers start with higher baseline risk - so the absolute benefit is larger.

This directly affects dementia risk too:
Every stroke, mini-stroke, or perfusion injury accelerates neurodegeneration.

Protecting the vascular system protects the brain.

Add to that -

• APOE4 brains exhibit impaired lipid recycling

• E4 astrocytes secrete less ApoE protein

• E4 carriers have more oxidized lipids and vascular inflammation

• E4 neurons accumulate cholesterol in membranes and endosomes

• E4 brains clear amyloid less effectively when lipids are dysregulated

Lowering peripheral LDL reduces one of the largest drivers of that dysregulation:
cholesterol flux through the vascular system.

This is why neurologists like Dr. Richard Isaacson have begun recommending low-dose statins even in normal LDL APOE4 patients, with a target LDL around 70–90 mg/dL when vascular risk is elevated.”

Fact: Most APOE4 carriers benefit from lower doses, not the outdated 20–40 mg prescriptions.

This is exactly what Dr. Isaacson said in a 2024 interview:

“You get about 85% of the LDL-lowering power at just 5 mg. Most people don’t need - and shouldn’t be on - 20 mg.”

This aligns with my own protocol, I take 10mg Pravastatin (a lower intensity statin).

• Ezetimibe daily (to block sterol hyperabsorption - common in E4)

• Low-dose statin 2–4× weekly (to lower hepatic cholesterol synthesis)

This combination gives us the metabolic benefit without the muscle/joint/cognitive side effects that come with traditional high-dose therapy.

The Bottom Line

Here is my data-driven conclusion:

APOE4 carriers, especially 4/4, appear to gain unique and stronger cognitive protection from statins.

The 2024 Neurology study makes that unmistakably clear.

Multiple cohorts and meta-analyses confirm slower cognitive decline in E4 carriers using statins.

APOE4 dramatically increases cardiovascular risk - and statins directly offset that.

Low-dose regimens work beautifully and avoid the side effects most people fear.

So when someone says:

“Statins don’t help APOE4s”, or, “we don’t need statins”
The correct response is:

Those claims directly contradict the strongest human data we have.
APOE4 carriers are the only group that consistently shows cognitive benefit.

Summary / Key References

Alzheimer’s / cognition - APOE4-specific benefit from statins

a) Rajan et al., Neurology, 2024 - “Statin Initiation and Risk of Incident Alzheimer Disease … in Genetically Susceptible Older Adults”

• Design: Population-based longitudinal cohort, 4,807 adults (~72 y at baseline) in Chicago, followed for incident AD and cognitive decline.

• Key finding overall: Starting a statin was associated with 19% lower risk of incident AD vs non-users (HR 0.81; 95% CI 0.70–0.94).

• APOE4 interaction:

  • APOE4 carriers: HR for AD with statin initiation 0.60 (95% CI 0.49–0.74)

  • Non-carriers: HR 0.96 (95% CI 0.82–1.12)

  • Interaction p-value = 0.015, meaning the protective association is significantly stronger in ε4 carriers.

• They also saw slower decline in global cognition and episodic memory after statin initiation only in APOE4 carriers, not in non-carriers.

Translation: in this large, real-world cohort, APOE4 carriers who started statins had meaningfully less AD and slower cognitive decline; non-carriers didn’t see a clear benefit.

b) Meta-analysis + cohort data summarized in Jamshidnejad-Tosaramandani et al., Frontiers in Aging Neuroscience, 2022

This review on statins and cognition pulls together several key points:

• A meta-analysis (Xuan et al., 2020) is reported as showing more cognitive benefit from statins in APOE4 carriers and in those with higher cholesterol levels.

• A longitudinal study in older Australians (Samaras et al., 2019):

  • In APOE4 carriers, statin use was associated with a slower rate of global cognitive decline over 6 years vs non-users.

  • In non-carriers, there was no meaningful difference between statin users and non-users. Frontiers

• Another study (Dagliati et al., 2020) found that only APOE4-carrier statin users showed a slightly lower risk of AD and dementia, particularly in men.

Translation: Across multiple datasets, APOE4 carriers look like the group that gains more cognitive protection from statins, especially when cholesterol is high.

c) Re-analysis of AD trials – greater benefit in APOE4/4

A PLoS One paper on evolocumab + statins (Korthauer et al., 2022) reviews prior data and notes:

• A re-analysis of patient-level data from multiple AD clinical trials found that long-term statin use was associated with less cognitive decline, with potentially greater benefit in APOE4/4 homozygotes. PLOS+1

The same Scientific Reports meta-analysis on statins and dementia (Chu et al., 2018) concludes overall that:

• Statin use is associated with reduced risk of all-type dementia, AD, and MCI in the general population.

• They highlight a study where AD patients with APOE4/4 appear to derive more benefit from statins than other genotypes. Nature

Translation: in AD patients and high-risk populations, statins reduce dementia risk overall, and the limited genotype-stratified data suggest extra benefit in APOE4/4.

d) Mechanistic review specifically about APOE4 + lipid-lowering

Menéndez-González et al., Int J Mol Sci, 2024, review how APOE4 alters cholesterol transport, Aβ handling, and AD risk, and discuss lipid-lowering therapies in APOE4 carriers. MDPI

• They emphasize that hyperlipidemia and APOE4 together amplify dementia risk, and

• Argue that aggressive management of cholesterol (statins ± ezetimibe / PCSK9) is a logical cornerstone in APOE4 patients, even though RCTs have not been genotype-tailored yet.

Cardiovascular benefit - why APOE4 makes statin LDL-lowering more important

a) APOE4 sharply raises vascular risk

Apolipoprotein E4 is not just a brain story. Kaufman et al. (2021) summarize that APOE4 carriers have higher risk of dyslipidemia, coronary artery disease, myocardial infarction, and both ischemic and hemorrhagic stroke, in addition to higher AD risk. https://pmc.ncbi.nlm.nih.gov/articles/PMC8387316

So your baseline ASCVD risk is higher if you’re E4, independent of AD.

b) Statins clearly reduce events - and APOE4 doesn’t “block” that benefit

• Large statin trials and meta-analyses show that LDL-C reduction ~70 mg/dL (1.8 mmol/L) translates into roughly a 60% reduction in major cardiac events and ~17% reduction in stroke risk with long-term therapy.

• The cardiovascular benefit of statins has not been shown to be diminished in APOE4 carriers; if anything, because baseline risk is higher, absolute benefit is larger for E4s at the same LDL level.

• 2025 data in European J. Preventive Cardiology show that people who used statins consistently for primary prevention had significantly fewer serious heart-disease events than inconsistent users.

And finally, a quick word about Lean Mass Hyper-Responders (LMHRs): the idea that an LDL of 200–300 mg/dL is “harmless” simply because someone is lean, fit, and metabolically healthy is not supported by long-term outcome data, in fact, such data doesn’t exist. LMHR is a phenotype, not a shield against atherosclerosis. We have decades of evidence, including Mendelian randomization, longitudinal imaging studies, and genetic models - showing that chronically elevated LDL drives plaque formation regardless of body composition or insulin sensitivity. Being metabolically healthy may reduce some risk, but it does not eliminate the biology of LDL particles penetrating the arterial wall. High LDL still accelerates vascular aging, and APOE4 only amplifies that process. In other words: LMHR may explain why, in some, LDL skyrockets on keto - but it doesn’t make that elevation safe.

Translation: APOE4 gives us more atherosclerotic risk; statins still cut that risk down. The combination “APOE4 + statins + LDL reduction” is a net win for heart and brain.

Noteworthy: For APOE4 carriers in particular, it’s worth noting that hydrophilic statins (such as Pravastatin and Rosuvastatin) are generally preferred because they do not readily cross the blood–brain barrier. This means they support cholesterol management without interfering with brain cholesterol metabolism - a key consideration for those of us focused on long-term cognitive protection.

In conclusion: Whether you decide to take a statin is your choice - but for me, it’s a clear and logical tool to counteract both my genetic risk and my lipid biology. Too many people talk about statins without any nuance. My aim isn’t to crush my cholesterol down to the extreme levels cardiologists target for their sickest cardiac patients. My aim is to give my body the support it needs to manage cholesterol it simply doesn’t process well on its own. That’s a rational, evidence-based strategy - especially for me, an APOE4 homozygote and a documented sterol/cholesterol hyper-absorber.

Addendum: Lipoprotein(a) - often overlooked but very important!

If you’ve tested lp(a) and it’s in normal range, you can skip reading this!

One critically important lipid marker was not addressed above - Lipoprotein(a), or Lp(a) - and it deserves special attention in the APOE4 population.

In fact, its omission in routine clinical care is one of the biggest blind spots in cardiovascular health.

Many physicians still do not test Lp(a) at all, despite decades of data showing that it is:

• Highly heritable

• Largely unresponsive to diet

• Independently atherogenic

• Strongly associated with both cardiovascular disease and vascular cognitive impairment

If you are APOE4 - especially APOE4/4 - this matters more than most people realize.

What is Lp(a), and why is it different from LDL?

Lp(a) is an LDL-like particle with an additional protein attached: apolipoprotein(a). That extra protein makes the particle uniquely dangerous because it combines:

• LDL-mediated cholesterol deposition

• Pro-inflammatory signaling

• Pro-thrombotic (clot-promoting) effects

In other words, Lp(a) is not just “more LDL.”
It is more inflammatory, more adhesive, and more damaging to blood vessels.

And unlike LDL, Lp(a) levels are set almost entirely by genetics. Diet, exercise, and weight loss have little effect.

Why APOE4 carriers should care even more

APOE4 already confers:

• Higher baseline vascular inflammation

• Impaired lipid clearance

• Endothelial dysfunction

• Increased stroke and microvascular injury risk

Now add elevated Lp(a), and you have a risk amplifier.

This matters for the brain.

Vascular injury - even subclinical, silent injury - accelerates:

• Blood–brain barrier breakdown

• White-matter disease

• Microinfarcts

• Amyloid deposition and impaired clearance

Every vascular insult compounds APOE4-related neurodegeneration.

The clinical problem: most people have never been tested

Lp(a) is:

• Not included in standard lipid panels

• Often dismissed unless someone already has heart disease

• Rarely discussed in prevention, especially in women

Many APOE4 carriers walking around with “normal LDL” have elevated Lp(a) and no idea they are at substantially higher lifetime risk.

Testing is simple. Interpretation is not.

Rough thresholds (units vary by lab):

• <30 mg/dL (or <75 nmol/L): lower risk

• 30–50 mg/dL: intermediate

• 50 mg/dL (or >125 nmol/L): clearly elevated risk

There is no “safe” elevated Lp(a) in an APOE4 carrier.

This is why lipid control becomes even more essential

Here’s the key point:

When Lp(a) is elevated, lowering LDL is no longer optional — it becomes compensatory risk management.

You cannot easily lower Lp(a) itself (yet).
So you lower everything else that feeds plaque formation.

That means:

• Lower LDL particle burden

• Lower ApoB

• Lower oxidized lipid flux

• Lower vascular inflammation

This is exactly where statins ± ezetimibe become strategically important for APOE4 carriers with elevated Lp(a).

Not because statins lower Lp(a) (they usually don’t), but because they reduce the atherogenic “background noise” that Lp(a) acts upon.

A critical nuance: statins and Lp(a)

Statins may modestly increase measured Lp(a) in some individuals.
This often causes confusion, unnecessary fear and causes some to stop statins altogether!

Despite this modest rise, statins still reduce cardiovascular events in people with high Lp(a) because:

• LDL reduction overwhelms the incremental Lp(a) signal

• Plaque progression slows

• Event rates fall

For APOE4 carriers, that vascular protection also translates into brain protection.

What about treatments that directly lower Lp(a)?

• PCSK9 inhibitors lower Lp(a) ~20–30% and substantially reduce events

• Antisense therapies (pelacarsen, olpasiran) are in late-stage trials and look very promising

• These will likely be game-changers for high-Lp(a) patients in the coming years

Until then, LDL/ApoB control is the primary lever we have.

Bottom line for APOE4 carriers

If you are APOE4 and have never had Lp(a) tested, that is an important gap in your risk assessment.

If Lp(a) is elevated:

• Your vascular and dementia risk is higher than LDL alone suggests

• Lipid management becomes more - not less - important

• Low-dose statins, ezetimibe, and thoughtful ApoB targets are rational, protective tools

If you have your DNA raw data file, you can look up the risk alleles for elevated lp(a):

rs10455872 G/G
rs3798220 C/C

Thirty-five years ago, I was diagnosed with Hashimoto’s Thyroiditis. The next decade was the most miserable period of my life. I was building a career, raising four children, and burning the candle at both ends. I battled intense anxiety, waves of physical symptoms, aches and pains, dry skin, brain fog, hair loss, brittle nails, constipation, poor sleep, and mood swings…to name just a few.

Fast forward to New Year’s Eve, 2000. I had just received the results of a fine-needle biopsy for a nodule on my right thyroid lobe. The letter from my endocrinologist said the biopsy was “inconclusive”…possible papillary thyroid cancer…and that surgery was recommended. Not exactly the way you want to ring in the 21st century.

Six weeks after surgery (the nodule was benign), I woke up in the middle of the night with the sensation of a frog leaping around in my chest. The next day my doctor confirmed new-onset atrial fibrillation. A same-day referral to a cardiologist ended with a beta blocker and blood thinner prescription, and the warning that I might need to take these for life. Diagnosis: “Lone Atrial Fibrillation,” meaning no known cause. I had absolutely no doubt it was tied to my thyroid lobectomy and thyroid status. My cardiologist vehemently disagreed.

The minute I arrived home, I searched for a functional medicine doctor. Until I could see her, I took a daily aspirin to reduce clot risk. When I told her I was on Synthroid (T4-only medication), she immediately switched me to NDT - natural desiccated thyroid, which contains both T4 and active T3. Within two weeks, my Afib episodes disappeared. They never returned.

This was my first lesson that taking T4 alone (an inert storage hormone until it’s converted into T3) doesn’t guarantee your body will convert it into the active hormone your brain actually needs: T3 and it was also my introduction to functional medicine….aimed at fixing problems instead of patching them. T4/T3 a bit like having a box of spaghetti in the cupboard (T4) which are unusable until they’re cooked (i.e. converted to T3).

Today I want to shine a light on the genetic variants that determine how efficiently you convert T4 to T3—and why this matters profoundly for anyone, but especially for those of us with APOE4. These genes are a reason we often see clusters of thyroid dysfunction within families and even multiple generations.

If you aren’t converting well, your labs may look “normal” while your brain, mood, energy, sleep, and metabolism pay the price.

The Two Genes That Control T4 → T3 Conversion

Two deiodinase enzymes activate thyroid hormone:

1. DIO1 — converts T4 → T3 in the liver, kidneys, and thyroid

2. DIO2 — converts T4 → T3 inside the cells, especially in the brain

Think of them as the body’s hormone-processing plant.

If you have variants in either of these genes, you may have plenty of circulating T4 but still experience:

• Low intracellular T3

• Low brain T3

• High reverse T3

• Anxiety

• Brain fog

• Depression

• Poor sleep

• Feeling hypothyroid despite normal labs

• Needing T3 (Cytomel) to feel normal

DIO2 rs225014 (Thr92Ala): The Game-Changer for APOE4

Risk allele: A

• CA = moderate reduction

• AA = most impaired

This variant:

• Reduces T4→T3 conversion inside the brain

• Is linked to depression, cognitive slowing, and memory issues

• Predicts poor response to T4-only therapy

• Strongly predicts who thrives on combination therapy (T4 + T3)

For APOE4s—who already have:

• reduced brain glucose metabolism

• higher neuroinflammation

• greater mitochondrial strain

—adding low brain T3 on top of that is a perfect storm.

If a tiny bit of Cytomel feels transformative, this SNP is often the reason.

DIO1: Lower T3, Higher Reverse T3

Key SNP: DIO1 rs2235544
Risk allele: A

Effects:

• Lower T3

• Higher reverse T3

• Sluggish peripheral conversion

• Difficulty clearing excess T4

This explains why many APOE4s struggle on:

• high-dose T4

• T4-only therapy

• generic levothyroxine

• slow-titration approaches

Why APOE4 Brains Are Especially Sensitive to Low T3

This is the part an endocrinologist rarely discusses—yet it’s critical.

APOE4 brains naturally have:

• reduced glucose uptake

• increased oxidative stress

• higher neuroinflammation

• impaired lipid transport

• greater mitochondrial burden

T3 is the hormone that:

• boosts mitochondrial energy

• supports synaptic formation

• regulates myelination

• enhances memory and mood

• increases neuroplasticity

• modulates inflammation

• supports temperature and metabolism

If your brain can’t convert T4 to T3 efficiently?

Cognition suffers silently—even when labs look perfect.

For an APOE4 carrier, this is the last thing we need.

The Thyroid Pattern: A Signature Profile

Across the thyroid dysfunction community, we see the same story:

• Normal TSH

• Normal T4

• Low-normal T3

• Ongoing symptoms

• Dramatic improvement with a small dose of T3

Endocrinologists often dismiss this as psychological.
Mine did too—25 years ago.

It wasn’t psychological.
It was genetics + brain energy biology.

Common symptoms when DIO1/DIO2 are impaired:

• Waking at 2–3 AM (very typical)

• Palpitations from low intracellular T3

• Cold intolerance

• Anxiety

• Slow gut motility

• Poor exercise tolerance

• Low deep sleep

• Needing T3 at bedtime to sleep (extremely common in DIO2 variants)

Does this sound familiar?
It’s almost a clinical fingerprint.

Why This Matters for Alzheimer’s Prevention

For APOE4 carriers, thyroid optimization is brain optimization.

T3 supports:

• neuronal energy

• cognition and memory

• mood

• amyloid clearance

• synaptic repair

• mitochondrial efficiency

• BDNF

• microglial function

Low T3 is not just a thyroid issue—it is a brain energy crisis.

And conversion naturally worsens with age.

Important SNPs to Know

DIO2 rs225014 (Thr92Ala) * the big one!
Risk allele: C (or G, depending on the lab report)
TC (Thr/Ala) = moderate reduction
CC (Ala/Ala) = most impaired

On most consumer reports, T = normal and C = risk at rs225014.

DIO2 rs12885300
Risk allele: C (or G)

DIO1 rs2235544
Risk allele: T (or A)

DIO1 rs11206244
Risk allele: T (or A)

Any of these—especially DIO2 variants—can make T4-only therapy ineffective.

What APOE4s Should Consider

1. Check your genetics

If you have your DNA data, check your genetics!

2. If you have symptoms + a DIO2 variant → consider combination therapy

Many APOE4s thrive on:

• T4 + low-dose T3

• NP Thyroid + Cytomel

• Time-released T3

• Split dosing

• Bedtime T3 for sleep regulation

3. Watch reverse T3

High rT3 = impaired conversion.

4. Track your deep sleep

Low T3 often appears as:

• Low deep and REM

• Middle-of-the-night waking

5. Avoid high-dose T4 if DIO1/DIO2 are impaired

Increasing T4 can worsen symptoms.

6. Work with someone who understands genetics

Most endocrinologists do not.
Good functional providers often do.

Final Thoughts

For APOE4 carriers, optimal thyroid function is non-negotiable.
If you don’t convert T4 into T3 efficiently—due to genetics, age, inflammation, or stress—your brain feels it long before your labs do.

Understanding your DIO1 and DIO2 status can explain years or decades of mysterious symptoms and transform:

• cognition

• sleep

• energy

• mood

• metabolism

• long-term brain resilience

This is one of the most overlooked tools in the APOE4 prevention toolkit.

My own thyroid has been optimized for years now.
I owe that to the late Dr. Christine Gustafson in Alpharetta, GA—a compassionate, brilliant functional medicine trailblazer who gave me my life back. She’s been gone for over 13 years, but I think of her often and remain forever grateful.

Today, I take enough NDT to keep my T4 in range—but at the very low end.
Keeping T4 low also keeps reverse T3 low, since rT3 is made from excess T4.
I take Cytomel (T3), splitting my dose: T3 in the morning and my NDT (which also contains some T3) at bedtime.

For me—and for many APOE4s—this has been life-changing.

Inside every cell is a hidden system that organizes life using the same physics we see when oil separates from water. Scientists call this phase separation, and it turns out to be one of the most important discoveries in understanding Alzheimer’s disease — especially for those of us with APOE4.

Here’s the simplest way to understand it:

1. Proteins behave like liquids — not rigid objects

Clifford Brangwynne (Princeton) discovered that many structures inside the cell are not “solid.” They behave like droplets — little liquid bubbles inside the cell.

These droplets help proteins stay organized, flexible, and functional.

Think of them like tiny gelatin bubbles that keep the cell tidy and running smoothly.

2. Healthy proteins constantly move between two states

Proteins naturally switch between:

• Liquid state → flexible, moving, dissolving

• Gel-like state → slightly thicker, more structured

This switching is normal and essential. It’s how our cells organize work, just like rearranging items on a desk.

3. But stress, aging, inflammation, or genetics (like APOE4) can “push” proteins too far

Sometimes, the droplets harden.
They stop being liquid.
They turn into sticky gels, and then eventually solid clumps.

That’s the moment phase separation becomes dangerous. (or, as Doris Loh refers to in her many melatonin discussions, this is when phase separation becomes aberrant.)

Hardened droplets can turn into:

• Tau tangles

• Amyloid plaques

• TDP-43 aggregates

These are the exact proteins that drive Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

4. Alzheimer’s is partly a problem of droplets turning into thick sludge.

This is the key idea:
Alzheimer’s is not just about “too much amyloid” — it’s about proteins losing their liquid flexibility and becoming stuck.

If the cell can’t keep proteins in their healthy liquid state, the system becomes clogged — like a kitchen sink filled with hardened grease.

This concept explains:

• why aging increases risk

• why inflammation makes things worse

• why stress granules “freeze” under chronic stress

• why APOE4 brains accumulate sticky proteins earlier

It’s not just about quantity; it’s about phase — liquid vs solid.

5. The hopeful part: phase separation can be influenced

This is where the field is exploding with optimism.

Many interventions some of us already use support the “liquid state” and protect against harmful hardening:

✔️ Melatonin

Powerful regulator of protein folding, mitochondrial protection and autophagy.

✔️ Red light therapy (PBM)

Supports mitochondria → reduces cellular stress → stabilizes healthy liquid droplets.

✔️ Omega-3 DHA & phosphatidylcholine

Keep membranes fluid; reduce “stickiness” of proteins; improve synaptic repair.

✔️ Ketones & metabolic flexibility

Reduce oxidative stress → fewer proteins pushed into hardened states.

✔️ Exercise

Upregulates heat-shock proteins that literally function as “protein lifeguards.”

✔️ Good sleep

Protects protein clearance and prevents stress-granule hardening.

In other words — there are many things that help proteins stay liquid, flexible, and non-toxic.

6. Why APOE4 matters here

APOE4 affects lipid metabolism and cellular stress handling.
APOE4 brains have:

• higher baseline inflammation

• impaired lipidation

• more stress granules

• more rapid collapse from liquid → solid states

• impaired cleanup systems (autophagy, lysosomes)

This makes phase separation more fragile in APOE4 individuals — and more important to protect.

7. The big picture

Phase separation is the physics that underlies Alzheimer’s.
If proteins stay in their liquid, dynamic state, the brain remains healthy and resilient.

If they harden into clumps, cognitive decline accelerates.

This is why a good protocol of sleep, melatonin, red light, DHA, fasting window, autophagy support, mitochondrial repair — is not fad wellness.

It is directly targeting the physics behind neurodegeneration. All of the above is already part of my protocol. How many of you are incorporating these tools in your prevention program?

https://pubmed.ncbi.nlm.nih.gov/38167731/
https://pubmed.ncbi.nlm.nih.gov/35181198/
https://pubmed.ncbi.nlm.nih.gov/36702317/